Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 2620
interventional 2294
Observational 300
Registry 26

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 1309
Drug|placebo 143
Drug|Radiation 121
Biological|Drug 107
Biological 81
Radiation 76
Drug|Other 59
Procedure 49
Drug|Procedure 43
Other 35
Biological|Drug|Other 21
Drug|Procedure|Radiation 19
Device 18
Behavioral 13
Biological|Drug|placebo 13
Biological|Drug|Radiation 11
Biological|Other 11
Diagnostic Test 9
Drug|Other|placebo 9
Drug|Other|Procedure 9
Drug|placebo|Radiation 8
Other|Procedure 8
Procedure|Radiation 8
Biological|placebo 7
Device|Drug 7
Drug|Other|Radiation 7
Biological|Radiation 6
Other|Radiation 6
Combination Product 5
Other|Procedure|Radiation 5
Dietary Supplement 4
Behavioral|Other|Procedure 3
Biological|Other|Radiation 3
Diagnostic Test|Drug 3
Drug|Genetic|Other 3
Drug|Other|Procedure|Radiation 3
Genetic 3
Behavioral|Drug|placebo 2
Biological|Dietary Supplement|Drug 2
Biological|Drug|Other|placebo 2
Biological|Drug|Other|Radiation 2
Biological|Other|Procedure|Radiation 2
Combination Product|Drug 2
Device|Drug|Radiation 2
Device|Other 2
Dietary Supplement|Drug 2
Drug|Genetic|Other|Procedure 2
Behavioral|Drug|Other|placebo 1
Behavioral|Drug|Other|Procedure 1
Behavioral|Radiation 1
Biological|Combination Product|Drug|Other 1
Biological|Device 1
Biological|Device|Drug|Radiation 1
Biological|Diagnostic Test 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Other|Procedure 1
Biological|Drug|placebo|Radiation 1
Biological|Drug|Procedure 1
Biological|placebo|Radiation 1
Biological|Procedure 1
Combination Product|Other 1
Device|Drug|Other 1
Device|Drug|Other|Procedure 1
Device|Drug|Procedure|Radiation 1
Device|Other|Radiation 1
Device|Procedure 1
Device|Radiation 1
Diagnostic Test|Drug|Other 1
Diagnostic Test|Other|Procedure 1
Dietary Supplement|Drug|Radiation 1
Dietary Supplement|placebo 1
Drug|Genetic 1
Drug|Genetic|Other|placebo 1
Drug|Genetic|Other|Procedure|Radiation 1
Drug|Genetic|Procedure 1
Drug|Other|placebo|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 861
China 270
NA 83
France 75
Canada 49
Japan 41
United States|Canada 40
Korea, Republic of 38
Italy 30
United Kingdom 30
Germany 29
Netherlands 28
Taiwan 21
Greece 18
Spain 15
Belgium 14
Australia 13
Denmark 10
Switzerland 9
India 7
United States|Spain 7
Israel 6
Poland 6
Singapore 6
United States|Germany 6
United States|United Kingdom 6
Norway 5
Russian Federation 5
United States|Puerto Rico 5
United States|China 4
Austria 3
Brazil 3
Sweden 3
United States|France 3
United States|India 3
United States|Korea, Republic of 3
United States|Netherlands 3
Argentina 2
China|Japan|Korea, Republic of|Taiwan 2
China|Korea, Republic of|Taiwan 2
China|Korea, Republic of|Thailand 2
Finland 2
France|Germany 2
Germany|Switzerland 2
Hong Kong 2
Hong Kong|Korea, Republic of|Singapore|Taiwan|Thailand 2
Mexico 2
Romania 2
Turkey 2
United States|Australia 2
United States|Australia|Brazil|Bulgaria|Canada|China|France|Germany|Greece|Hong Kong|Hungary|Ireland|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Sweden|Taiwan|United Kingdom 2
United States|Australia|Canada 2
United States|Australia|Japan|Korea, Republic of 2
United States|Australia|Korea, Republic of|Taiwan 2
United States|Australia|Peru|Puerto Rico 2
United States|Canada|France|Germany|Italy|Spain|United Kingdom 2
United States|Canada|Puerto Rico 2
United States|Canada|Spain|United Kingdom 2
United States|France|Hungary|Poland|Spain 2
United States|Georgia|India|Russian Federation|Ukraine 2
United States|Italy 2
United States|Japan 2
United States|Russian Federation 2
United States|Taiwan 2
NA 1
Argentina|Australia|Austria|Belgium|Brazil|China|Finland|France|Germany|Hungary|India|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Peru|Poland|Russian Federation|Spain|Taiwan|Ukraine|United Kingdom 1
Argentina|Australia|Austria|Brazil|China|Colombia|Denmark|France|Germany|Greece|Hungary|India|Ireland|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Netherlands|Norway|Poland|Portugal|Russian Federation|Singapore|Spain|Sweden|Taiwan|Thailand|Turkey|United Kingdom 1
Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Czech Republic|France|Germany|Greece|Hong Kong|Hungary|Israel|Italy|Poland|Russian Federation|Spain|Taiwan|Thailand|United Kingdom 1
Argentina|Australia|Brazil|Canada|Romania|Singapore 1
Argentina|Belgium|Brazil|Bulgaria|Canada|China|Colombia|Czechia|Denmark|Germany|India|Ireland|Italy|Kazakhstan|Luxembourg|Mexico|Poland|Portugal|Romania|Slovakia|Spain|Switzerland|United Kingdom|Vietnam 1
Argentina|Brazil|Chile|Mexico 1
Argentina|Brazil|China|Colombia|Costa Rica|Denmark|Greece|Guatemala|Italy|Latvia|Lebanon|Malaysia|Mexico|Morocco|Netherlands|Panama|Peru|Philippines|Poland|Slovenia|Spain|Sweden|United Arab Emirates|United Kingdom 1
Australia|Austria|Belgium|Canada|Chile|China|Czech Republic|Denmark|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Lithuania|Malaysia|New Zealand|Poland|Romania|Russian Federation|Slovakia|Slovenia|South Africa|Spain|Ukraine|United Kingdom|Venezuela 1
Australia|Austria|Czechia|Greece|Hungary|Israel|Italy|Poland|Portugal|Russian Federation|Spain 1
Australia|Belgium|Canada|Czech Republic|Denmark|France|Germany|Hong Kong|Hungary|Italy|Netherlands|Poland|Russian Federation|Spain|Taiwan|United Kingdom 1
Australia|Belgium|China|France|Germany|Israel|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|Thailand 1
Australia|Belgium|China|Germany|Japan|Singapore|Spain 1
Australia|Belgium|Finland|France|Germany|Greece|India|Italy|Netherlands|Poland|Portugal|Romania|Spain|Turkey|United Kingdom 1
Australia|Belgium|France|India|Japan|Malaysia|Spain|Taiwan|Thailand 1
Australia|Belgium|France|Italy|Korea, Republic of|Lithuania|Netherlands|Poland|Romania|Singapore|Spain|Taiwan|United Kingdom 1
Australia|Belgium|Germany 1
Australia|Brazil|China|Korea, Republic of|Mexico|Taiwan 1
Australia|Brazil|Czech Republic|France|Germany|Italy|Korea, Republic of|South Africa|Taiwan|United Kingdom 1
Australia|Canada 1
Australia|Canada|Czech Republic|Netherlands|United Kingdom 1
Australia|China|Egypt|India|Korea, Republic of|Romania|Taiwan|Turkey 1
Australia|China|Hong Kong|Indonesia|Korea, Republic of|Philippines|Taiwan|Thailand 1
Australia|China|Korea, Republic of 1
Australia|Hong Kong|Korea, Republic of|Singapore 1
Australia|Italy|Mexico|Spain 1
Australia|Korea, Republic of|Malaysia 1
Australia|Netherlands|Singapore 1
Australia|New Zealand 1
Australia|New Zealand|Poland|Russian Federation|Thailand 1
Australia|New Zealand|Spain 1
Australia|Singapore 1
Australia|Taiwan 1
Australia|United Kingdom 1
Australia|United States|Austria|Belarus|Brazil|Canada|Croatia|Czechia|Denmark|Egypt|Estonia|Finland|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Latvia|Lithuania|Mexico|Netherlands|New Zealand|Norway|Poland|Portugal|Puerto Rico|Russian Federation|Serbia|Slovakia|South Africa|Spain|Sweden|Switzerland|Turkey|Ukraine|United Kingdom 1
Austria|Australia|Belgium|Canada|China|Czech Republic|Denmark|Finland|France|Germany|Greece|Hungary|Israel|Italy|Latvia|Lithuania|Netherlands|New Zealand|Philippines|Poland|Portugal|Russian Federation|Singapore|South Africa|Spain|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
Austria|Belgium|Denmark|France|Germany|Netherlands|Norway|Switzerland|United Kingdom 1
Austria|Belgium|Denmark|Greece|Hungary|Ireland|Israel|Italy|Netherlands|Spain|Switzerland|United Kingdom 1
Austria|Belgium|France|Germany|Ireland|Italy|Poland|Slovenia|Spain|Switzerland|United Kingdom 1
Austria|Denmark|Finland|Greece|Hungary|Ireland|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|United Kingdom 1
Austria|Denmark|France|Germany|Italy|Spain 1
Austria|Germany|Greece|Italy|Netherlands|Spain 1
Austria|Germany|Hungary|Spain|Sweden 1
Bahamas|Canada 1
Bangladesh 1
Belarus|Bulgaria|Croatia|Georgia|Greece|Hungary|India|Latvia|Malaysia|Philippines|Poland|Russian Federation|Serbia|Slovakia|Thailand|Turkey|Ukraine 1
Belarus|Georgia|Germany|Hungary|Korea, Republic of|Poland|Romania|Russian Federation|Serbia|Spain|Taiwan|Thailand|Ukraine 1
Belarus|Hungary|Poland|Russian Federation|Ukraine 1
Belarus|India|Russian Federation|Ukraine 1
Belarus|Russian Federation 1
Belgium|Bosnia and Herzegovina|Bulgaria|Egypt|Estonia|Germany|Hungary|Italy|Lithuania|Poland|Romania|Saudi Arabia|Slovakia|Sweden|Taiwan 1
Belgium|Bulgaria|Estonia|France|Germany|Hong Kong|Ireland|Italy|Poland|Russian Federation|Singapore|Spain|Taiwan|United Kingdom 1
Belgium|Bulgaria|France|Germany|Hong Kong|Hungary|Italy|Korea, Republic of|Norway|Poland|Portugal|Russian Federation|Slovakia|Spain|Turkey 1
Belgium|China|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Netherlands|Poland|Portugal|Spain|Taiwan|Thailand|United Kingdom 1
Belgium|Czech Republic|Egypt|France|Germany|Greece|Italy|Netherlands|Poland|South Africa|Spain|Switzerland 1
Belgium|Czech Republic|France|Germany|Ireland|Italy|Poland|Spain 1
Belgium|Denmark|Netherlands|Sweden|United Kingdom 1
Belgium|Estonia|Finland|France|Germany|Greece|Italy|Latvia|Lithuania|Netherlands|Norway|Poland|Spain|United Kingdom| 1
Belgium|France 1
Belgium|France|Germany|Italy|Poland|Spain|United Kingdom 1
Belgium|France|Greece|Spain 1
Belgium|France|Italy|Netherlands|United Kingdom 1
Belgium|France|Spain 1
Belgium|Germany|Luxembourg 1
Belgium|Germany|Netherlands 1
Belgium|Germany|Netherlands|Spain|Switzerland 1
Belgium|Germany|Switzerland|United Kingdom 1
Belgium|Ireland|Italy|Netherlands|Spain|Switzerland 1
Belgium|Ireland|Spain 1
Belgium|Netherlands 1
Belgium|Netherlands|United Kingdom 1
Belgium|Spain 1
Belgium|Spain|United Kingdom 1
Belgium|United States|Argentina|Australia|Brazil|Canada|Chile|China|Czechia|Denmark|France|Germany|Greece|Hungary|Israel|Italy|Japan|Jordan|Korea, Republic of|Lebanon|Netherlands|Poland|Russian Federation|Singapore|Spain|Taiwan 1
Belgium|United States|Argentina|Chile|France|Germany|Hungary|India|Italy|Netherlands|Norway|Poland|Puerto Rico|Romania|Russian Federation|South Africa|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
Brazil|Bulgaria|Chile|Georgia|Greece|Hungary|India|Lebanon|Malaysia|Mexico|Philippines|Russian Federation|Serbia|Spain|Thailand|Turkey|Ukraine 1
Brazil|Bulgaria|China|Lithuania|Mexico|New Zealand|Poland|Russian Federation|Slovakia|Turkey 1
Brazil|Canada 1
Brazil|China|Hong Kong|India|Korea, Republic of|Taiwan|United Kingdom 1
Bulgaria 1
Bulgaria|Czech Republic|France|Romania|Ukraine 1
Bulgaria|France|Greece|Hungary|Italy|Norway|Poland|Portugal|Romania|Spain|Switzerland|Turkey|United Kingdom 1
Canada|Germany|Hong Kong|Italy|Singapore|Taiwan 1
Canada|Hungary|Poland|Romania 1
Canada|Italy 1
Canada|Korea, Republic of|Taiwan 1
Canada|United States|Brazil|Germany|Korea, Republic of|Poland|Romania|Russian Federation|United Kingdom 1
Canada|United States|Japan|Romania|South Africa 1
Chile|China|Croatia|Egypt|India|Malaysia|Malta|Morocco|Pakistan|Panama|Peru|South Africa|Tunisia 1
Chile|France|Italy|Korea, Republic of|Latvia|New Zealand|Poland|Spain|United Kingdom 1
China|Austria|Belarus|Belgium|Bulgaria|Croatia|Czechia|Denmark|France|Georgia|Germany|Greece|India|Israel|Italy|Korea, Republic of|Lithuania|Poland|Portugal|Romania|Russian Federation|Slovakia|South Africa|Spain|Switzerland|Ukraine|United Kingdom 1
China|Denmark|Egypt|France|Germany|Netherlands|Spain|Switzerland|Turkey 1
China|France|Germany|Hong Kong|Hungary|Italy|Japan|Korea, Republic of|Russian Federation|Spain|Taiwan 1
China|Hong Kong|India|Philippines|Taiwan|Thailand|Vietnam 1
China|Hong Kong|India|Singapore|Taiwan 1
China|Hong Kong|Indonesia|Japan|Malaysia|Philippines|Singapore|Taiwan|Thailand 1
China|Hong Kong|Indonesia|Korea, Republic of|Philippines|Taiwan|Thailand 1
China|Hong Kong|Malaysia|Taiwan|Thailand 1
China|Hong Kong|Russian Federation|Singapore 1
China|Italy|Korea, Republic of|Malaysia|Singapore|Spain|Taiwan 1
China|Korea, Republic of 1
China|Korea, Republic of|Malaysia|Singapore|Thailand 1
China|Malaysia 1
China|Malaysia|Philippines 1
China|Thailand 1
China|United States|Australia|Belgium|Brazil|Bulgaria|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Malaysia|Philippines|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom|Vietnam 1
China|United States|Australia|Belgium|Brazil|Canada|France|Germany|Hong Kong|Hungary|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Romania|Russian Federation|Spain|Sweden|Taiwan|Thailand|Turkey|Ukraine|Vietnam 1
China|United States|Australia|Canada|France|Germany|Hong Kong|Hungary|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Russian Federation|Spain|Sweden|Taiwan|United Kingdom 1
Cyprus 1
Czech Republic|Germany|Netherlands 1
Czech Republic|United States|Australia|Bulgaria|Canada|France|Germany|Greece|Hungary|India|Italy|Korea, Republic of|Latvia|Malaysia|Philippines|Poland|Romania|Russian Federation|Singapore|Spain|Taiwan|Turkey|United Kingdom 1
Denmark|France|Germany|Italy|Korea, Republic of|Netherlands|Spain|Taiwan|United Kingdom 1
Denmark|Germany|Italy|Spain|Sweden 1
Denmark|United Kingdom 1
Egypt 1
Egypt|Estonia|Argentina|Australia|Austria|Bosnia and Herzegovina|Brazil|Canada|China|Colombia|Czech Republic|Denmark|Ecuador|Finland|France|Germany|Hong Kong|Hungary|Iceland|Israel|Italy|Latvia|Lebanon|Lithuania|Mexico|Netherlands|Poland|Portugal|Romania|Russian Federation|Serbia|Slovakia|Slovenia|Spain|Sweden|Switzerland|Taiwan|Turkey|United Kingdom|Venezuela 1
Egypt|Lebanon|Saudi Arabia 1
Egypt|Malaysia|Philippines|Poland|Romania|Serbia|Thailand 1
Finland|Germany|Italy|Netherlands|United Kingdom 1
France|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Chile|Czech Republic|Germany|Hong Kong|Hungary|Ireland|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Russian Federation|Singapore|Slovakia|Spain|Sweden|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom 1
France|Czechia|Germany|Greece|Italy|Poland|Romania|Spain 1
France|Germany|Greece|Italy|Korea, Republic of|Netherlands|Russian Federation|Spain|Sweden|Switzerland|Turkey|United Arab Emirates 1
France|Germany|Hungary|Poland 1
France|Germany|Italy|Netherlands|Spain|United Kingdom 1
France|Germany|Italy|Spain 1
France|Germany|Italy|Spain|United Kingdom 1
France|Germany|Spain 1
France|Italy|Spain 1
France|Jordan|Poland|Slovenia|Spain 1
France|Korea, Republic of|Spain 1
France|Korea, Republic of|Spain|United Kingdom 1
France|Switzerland|United Kingdom 1
France|United States|Argentina|Australia|Belgium|Brazil|Canada|China|Czechia|Germany|Ireland|Italy|Japan|Mexico|Netherlands|Poland|Puerto Rico|Romania|Russian Federation|Spain|Taiwan|United Kingdom 1
France|United States|Spain|United Kingdom 1
Georgia 1
Germany|Italy 1
Germany|Italy|Netherlands|Poland|United Kingdom 1
Germany|Italy|Poland|United Kingdom 1
Germany|Netherlands|Spain|Switzerland 1
Germany|Poland 1
Germany|Spain 1
Germany|United Kingdom 1
Germany|United States|Argentina|Belgium|Brazil|Canada|China|Croatia|Denmark|Estonia|France|Hong Kong|Indonesia|Italy|Latvia|Malaysia|Mexico|Philippines|Singapore|Slovenia|Spain|Sweden|Switzerland|Thailand|Turkey 1
Germany|United States|Argentina|France|Israel|Italy|Latvia|Spain|United Kingdom 1
Germany|United States|Austria 1
Germany|United States|Canada 1
Greece|Australia|Belarus|Brazil|Bulgaria|Chile|China|Colombia|Czechia|Georgia|Hungary|Jordan|Lebanon|Malaysia|Mexico|Philippines|Poland|Romania|Russian Federation|Spain|Taiwan|Thailand|Turkey|Ukraine 1
Greece|Germany|Australia|Austria|Belgium|Canada|Czech Republic|Estonia|Finland|France|Hong Kong|Hungary|Italy|Poland|Spain 1
Hong Kong|India|China|Korea, Republic of|Mexico|Philippines|Poland|Russian Federation|Taiwan|Turkey 1
Hong Kong|Korea, Republic of|Malaysia|Philippines|Singapore|Taiwan|Thailand 1
Hong Kong|Korea, Republic of|Malaysia|Singapore|Taiwan|Thailand 1
Hong Kong|Korea, Republic of|Taiwan|Thailand 1
Hungary|Poland|Russian Federation 1
Hungary|Serbia|Spain 1
Hungary|United States|Austria|France|Italy|Poland|Romania|Spain 1
Hungary|United States|Belgium|Czechia|Italy|Korea, Republic of|United Kingdom 1
Ireland 1
Ireland|Korea, Republic of|Netherlands|Singapore|Spain|Switzerland 1
Ireland|United Kingdom 1
Israel|Italy|Japan|United States|Belgium|Canada|China|France|Germany|Korea, Republic of|Netherlands|Poland|Spain|United Kingdom 1
Italy|Netherlands|Poland|South Africa|United Kingdom 1
Italy|Netherlands|Spain|United Kingdom 1
Italy|United States|Argentina|Australia|Austria|Canada|Chile|Czechia|France|Germany|Hungary|Ireland|Mexico|Netherlands|Peru|Poland|Romania|Russian Federation|Spain|United Kingdom 1
Italy|United States|France|Germany|India|Poland|Russian Federation|Ukraine 1
Japan|Brazil|Czechia|Hungary|India|Korea, Republic of|Mexico|Peru|Philippines|Poland|Russian Federation|Thailand|Turkey|Vietnam 1
Japan|Korea, Republic of|Singapore|Taiwan 1
Japan|Korea, Republic of|Taiwan 1
Japan|United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|China|France|Germany|Ireland|Italy|Mexico|Poland|Romania|Russian Federation|Spain|United Kingdom 1
Japan|United States|Argentina|Brazil|China|Hungary|India|Korea, Republic of|Malaysia|Peru|Russian Federation|Spain|Taiwan|Thailand|Turkey|Vietnam 1
Jordan|Lebanon 1
Kazakhstan|Russian Federation 1
Korea, Republic of|Poland 1
Mexico|United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Czechia|Denmark|France|Germany|Hungary|Italy|Netherlands|Peru|Poland|Romania|Russian Federation|Spain|Sweden|United Kingdom 1
Netherlands|Spain|Switzerland 1
Netherlands|United Kingdom 1
Peru|United States|Argentina|Australia|Brazil|Canada|Italy|Korea, Republic of|New Zealand|Philippines|Taiwan|Thailand 1
Poland|Albania|Argentina|Australia|Austria|Belgium|Bosnia and Herzegovina|Brazil|Bulgaria|Chile|China|Colombia|Croatia|Czech Republic|Ecuador|Egypt|Estonia|Finland|Germany|Greece|Guatemala|Hong Kong|Hungary|India|Indonesia|Ireland|Israel|Italy|Korea, Republic of|Latvia|Lithuania|Malaysia|Mexico|Netherlands|New Zealand|Panama|Peru|Portugal|Romania|Russian Federation|Saudi Arabia|Serbia|Slovakia|Slovenia|Sweden|Switzerland|Taiwan|Thailand|Turkey|Uruguay|Venezuela 1
Poland|Romania|South Africa|Ukraine 1
Poland|Russian Federation|United States|Australia|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Singapore|Spain|Taiwan|United Kingdom 1
Poland|Spain|China|Hong Kong|Italy|Japan|Korea, Republic of 1
Poland|Spain|United States|France|Italy|Japan 1
Poland|United States|Belarus|Bosnia and Herzegovina|Bulgaria|Croatia|Georgia|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Peru|Philippines|Romania|Russian Federation|Serbia|Spain|Taiwan|Thailand|Turkey|Ukraine|Vietnam 1
Portugal 1
Romania|Australia|Austria|Belgium|Canada|Chile|China|Czech Republic|Denmark|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Lithuania|Malaysia|Netherlands|New Zealand|Poland|Russian Federation|Slovakia|Slovenia|South Africa|Spain|Ukraine|United Kingdom|Venezuela 1
Russian Federation|Taiwan|United States|Austria|Belgium|Korea, Republic of|Poland|Thailand 1
Russian Federation|Ukraine 1
Serbia 1
Slovakia|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|France|Germany|Israel|Italy|Japan|Latvia|Lithuania|Mexico|Netherlands|Peru|Portugal|Russian Federation|Singapore|Spain|Taiwan|Ukraine 1
Spain|Austria|Belgium|Brazil|Canada|China|Cyprus|Finland|France|Germany|Greece|Hungary|Israel|Italy|Mexico|Netherlands|Switzerland|United Kingdom 1
Spain|Taiwan|United States|Argentina|France|Germany|Israel|Italy|Latvia|Malaysia|Mexico|Philippines|United Kingdom 1
Spain|United States|Argentina|Australia|Austria|Brazil|Canada|Chile|China|Colombia|Czechia|Denmark|Finland|France|Germany|Greece|Hong Kong|Hungary|Iceland|India|Italy|Japan|Korea, Republic of|Lebanon|Malaysia|Netherlands|Norway|Philippines|Poland|Portugal|Romania|Russian Federation|Singapore|Slovakia|South Africa|Sweden|Switzerland|Taiwan|Thailand|Turkey|United Kingdom|Vietnam 1
Spain|United States|Canada|Germany|Korea, Republic of|Taiwan 1
Sweden|United Kingdom 1
Turkey|United States|Australia|Belgium|Brazil|Canada|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Russian Federation|Singapore|Spain|Taiwan|United Kingdom 1
Ukraine|United Kingdom|United States|Belgium|Hungary|India|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Russian Federation 1
Ukraine|United States|Belarus|Belgium|Canada|Czechia|France|Germany|Hungary|Italy|Netherlands|Poland|Russian Federation|Serbia|Slovenia|Spain 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|France|Germany|Hungary|Israel|Italy|Mexico|Netherlands|Peru|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|France|Germany|Italy|Japan|Latvia|Lithuania|Mexico|Netherlands|Peru|Portugal|Russian Federation|Singapore|Slovakia|Spain|Switzerland|Taiwan|Ukraine 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|China|Colombia|Czechia|Finland|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Netherlands|Peru|Poland|Romania|Russian Federation|Saudi Arabia|South Africa|Spain|Switzerland|Taiwan|Turkey|United Arab Emirates|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|France|Germany|Hong Kong|Hungary|Ireland|Italy|Japan|Korea, Republic of|Malaysia|Peru|Philippines|Romania|Russian Federation|Taiwan|Thailand|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Czechia|Finland|France|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Romania|Spain|Sweden|Switzerland|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Finland|France|Germany|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Puerto Rico|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Chile|Colombia|Czech Republic|Egypt|Former Yugoslavia|France|Greece|Israel|Italy|Japan|Lithuania|Macedonia, The Former Yugoslav Republic of|Morocco|Norway|Philippines|Poland|Portugal|Slovenia|South Africa|Spain|Sweden|Switzerland|Tunisia 1
United States|Argentina|Australia|Austria|Belgium|Bulgaria|Chile|China|France|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Latvia|Lithuania|Malaysia|Netherlands|Peru|Portugal|Romania|Russian Federation|Spain|Taiwan|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Canada|China|France|Germany|Hong Kong|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Peru|Philippines|Singapore|Spain|Taiwan|Thailand|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Canada|Czech Republic|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Chile|China|Czech Republic|Estonia|Finland|France|Germany|Greece|Hong Kong|Hungary|India|Italy|Korea, Republic of|Malaysia|Netherlands|Poland|Portugal|Romania|Russian Federation|Singapore|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Australia|Austria|Brazil|Canada|Chile|Czechia|France|Germany|Hong Kong|Hungary|Italy|Mexico|Norway|Peru|Poland|Romania|Russian Federation|Singapore|Spain|Switzerland 1
United States|Argentina|Australia|Austria|Brazil|Canada|Colombia|France|Germany|Japan|Korea, Republic of|New Zealand|Poland|Romania|Russian Federation|Spain|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Brazil|Canada|France|Germany|Hungary|Italy|Japan|Korea, Republic of|New Zealand|Norway|Poland|Russian Federation|Spain|Switzerland|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Brazil|Denmark|France|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Peru|Poland|Russian Federation|Serbia|Spain|Switzerland|Taiwan|Thailand|Turkey|Ukraine 1
United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Chile|Colombia|Croatia|Czechia|Denmark|France|Hungary|Israel|Italy|Japan|Korea, Republic of|Mexico|Peru|Poland|Romania|Russian Federation|Slovakia|South Africa|Spain|Switzerland|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Hong Kong|Israel|Italy|Mexico|Philippines|Romania|Singapore|Spain|Taiwan|Thailand|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|Costa Rica|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|New Zealand|Panama|Peru|Poland|Russian Federation|Serbia|Singapore|Spain|Taiwan|Thailand|Turkey 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|Croatia|France|Germany|Hong Kong|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|Peru|Poland|Russian Federation|Serbia|South Africa|Spain|Taiwan|Ukraine|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|France|Germany|Greece|Ireland|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Puerto Rico|Romania|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Greece|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Romania|Russian Federation|Singapore|Spain|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Hong Kong|Israel|Italy|Korea, Republic of|Netherlands|Peru|Poland|Russian Federation|Spain|Turkey|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|France|Germany|Greece|India|Ireland|Korea, Republic of|Netherlands|Portugal|Spain|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Colombia|France|Germany|Hong Kong|Korea, Republic of|Mexico|Philippines|Singapore|Spain|Taiwan|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Czechia|Japan|Korea, Republic of|Netherlands|Spain|Taiwan 1
United States|Argentina|Australia|Belgium|Bulgaria|Canada|Chile|China|France|Hungary|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Turkey 1
United States|Argentina|Australia|Belgium|Canada|China|Czechia|France|Germany|Hong Kong|India|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Russian Federation|Singapore|Spain|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Australia|Belgium|Colombia|France|Germany|Greece|Hong Kong|India|Israel|Italy|Mexico|Philippines|Portugal|South Africa|Spain|Sweden|Taiwan|United Kingdom|Venezuela 1
United States|Argentina|Australia|Bosnia and Herzegovina|Brazil|Canada|Chile|Colombia|Ecuador|Germany|Hong Kong|Hungary|Ireland|Korea, Republic of|Latvia|Macedonia, The Former Yugoslav Republic of|Malaysia|Mexico|Moldova, Republic of|Netherlands|New Zealand|Panama|Peru|Philippines|Poland|Romania|Serbia|Sweden|Taiwan|Thailand|Turkey|Ukraine 1
United States|Argentina|Australia|Brazil|Canada|Chile|China|Germany|Greece|Israel|Mexico|New Zealand|Romania|Singapore|South Africa|Sweden|Thailand 1
United States|Argentina|Australia|Brazil|Canada|Chile|Colombia|France|Germany|Hungary|Ireland|Italy|Korea, Republic of|Latvia|Mexico|Peru|Poland|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Brazil|Canada|Chile|France|Germany|Hungary|Israel|Italy|Netherlands|Russian Federation|Spain|Ukraine|United Kingdom 1
United States|Argentina|Australia|Brazil|Canada|China|Czechia|India|Japan|Korea, Republic of|Peru|Philippines|Russian Federation|Slovakia|South Africa|Taiwan|Thailand|United Kingdom|Vietnam 1
United States|Argentina|Australia|Brazil|Canada|China|Denmark|France|Germany|Hong Kong|India|Indonesia|Italy|Korea, Republic of|Mexico|Netherlands|Norway|Philippines|Spain|Taiwan|Thailand|United Kingdom 1
United States|Argentina|Australia|Brazil|Chile|India 1
United States|Argentina|Australia|Canada|Czechia|Denmark|Finland|Germany|Hungary|Israel|Japan|Korea, Republic of|Netherlands|New Zealand|Russian Federation|South Africa|Spain|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Australia|France|Germany|Italy|Korea, Republic of|Russian Federation|Spain|Taiwan 1
United States|Argentina|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|China|France|Germany|Greece|Hong Kong|Hungary|India|Indonesia|Israel|Italy|Japan|Korea, Republic of|Netherlands|Pakistan|Peru|Philippines|Poland|Russian Federation|Singapore|South Africa|Spain|Sweden|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Argentina|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|China|France|Germany|Hungary|India|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Peru|Philippines|Romania|Russian Federation|Spain|Taiwan|Thailand|Vietnam 1
United States|Argentina|Austria|Belgium|Brazil|Canada|China|Denmark|France|Germany|Greece|India|Indonesia|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|Portugal|Singapore|Spain|Thailand|Turkey|Vietnam 1
United States|Argentina|Austria|Belgium|Brazil|Canada|France|Germany|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Netherlands|Norway|Poland|Russian Federation|Singapore|Spain|Sweden|Switzerland|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Austria|Belgium|Brazil|Denmark|France|Germany|Greece|Italy|Japan|Lebanon|Mexico|Netherlands|Oman|Slovakia|Spain|United Arab Emirates 1
United States|Argentina|Austria|Brazil|Bulgaria|Canada|Chile|China|Colombia|Czechia|France|Germany|Greece|Guatemala|Hong Kong|Hungary|Iceland|India|Israel|Italy|Japan|Jordan|Korea, Republic of|Lebanon|Malaysia|Mexico|Norway|Panama|Peru|Philippines|Poland|Portugal|Romania|Russian Federation|South Africa|Spain|Switzerland|Taiwan|Thailand|Turkey|United Kingdom|Vietnam 1
United States|Argentina|Austria|Brazil|Canada|Chile|Finland|France|Germany|Greece|Guatemala|Hungary|Italy|Japan|Korea, Republic of|Netherlands|New Zealand|Norway|Panama|Poland|Portugal|Russian Federation|Serbia|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Austria|Brazil|Canada|France|Germany|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Mexico|Netherlands|New Zealand|Norway|Poland|Puerto Rico|Romania|Russian Federation|Spain|Sweden|Switzerland|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Austria|Canada|Chile|China|Croatia|France|Germany|Greece|Hong Kong|Italy|Korea, Republic of|Mexico|Romania|Russian Federation|Spain|Sweden|Taiwan|Thailand 1
United States|Argentina|Austria|Canada|Chile|China|Denmark|France|Germany|Greece|Hungary|India|Ireland|Italy|Korea, Republic of|Mexico|Netherlands|Portugal|Singapore|Spain|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Belgium|Brazil|Canada|China|France|Germany|Greece|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Spain|Taiwan|Turkey|Ukraine 1
United States|Argentina|Belgium|Brazil|Canada|China|France|Germany|Ireland|Italy|Japan|Korea, Republic of|Poland|Romania|Russian Federation|South Africa|Spain|Taiwan|Ukraine|United Kingdom 1
United States|Argentina|Belgium|Brazil|Canada|France|Germany|Hong Kong|Hungary|Italy|Japan|Netherlands|Singapore|Spain|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Argentina|Belgium|Brazil|Canada|France|Germany|Israel|Italy|Netherlands|Spain|Turkey 1
United States|Argentina|Belgium|Germany|South Africa|United Kingdom 1
United States|Argentina|Brazil|Bulgaria|Chile|China|Denmark|Finland|Greece|Hong Kong|India|Israel|Japan|Korea, Republic of|Malaysia|Mexico|Peru|Philippines|Poland|Portugal|Qatar|Romania|Russian Federation|Saudi Arabia|Singapore|Sweden|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Brazil|Bulgaria|Chile|Colombia|Greece|Hungary|Mexico|Peru|Poland|Romania|Russian Federation|Spain|Turkey|Ukraine 1
United States|Argentina|Brazil|Bulgaria|Chile|Croatia|Egypt|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Philippines|Poland|Portugal|Romania|Russian Federation|Serbia|South Africa|Spain|Thailand|Turkey|Ukraine|United Kingdom|Vietnam 1
United States|Argentina|Brazil|Canada|China|France|Greece|Hungary|Italy|Japan|Korea, Republic of|Romania|Spain|Taiwan|Turkey 1
United States|Argentina|Brazil|Czech Republic|Hungary|India 1
United States|Argentina|Canada|France|Korea, Republic of|Poland|Spain|Taiwan 1
United States|Argentina|China|Korea, Republic of 1
United States|Argentina|France|Hungary|Spain|Thailand 1
United States|Australia|Austria|Belarus|Bosnia and Herzegovina|China|Denmark|Egypt|France|Germany|Greece|Hungary|Israel|Italy|Japan|Kazakhstan|Korea, Republic of|Latvia|Lebanon|North Macedonia|Poland|Portugal|Romania|Russian Federation|Saudi Arabia|Singapore|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Colombia|Czechia|Germany|Greece|India|Italy|Korea, Republic of|Lebanon|Malaysia|Netherlands|Poland|Russian Federation|Spain|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Canada|Croatia|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Philippines|Poland|Portugal|Romania|Russian Federation|Serbia|Singapore|Slovakia|South Africa|Spain|Taiwan|Thailand|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|Canada|Croatia|France|Germany|Greece|Hungary|Italy|Poland|Portugal|Romania|Russian Federation|Slovakia|South Africa|Spain|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|France|Germany|Netherlands 1
United States|Australia|Austria|Belgium|Canada|France|Israel|Italy|Spain 1
United States|Australia|Austria|Brazil|Bulgaria|China|Croatia|Czech Republic|Germany|Greece|Hungary|India|Italy|Korea, Republic of|Netherlands|Poland|Romania|Spain|Taiwan|Turkey 1
United States|Australia|Austria|Brazil|China|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Poland|Russian Federation|Serbia|Slovenia|South Africa|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Canada|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Spain|Sweden|Taiwan 1
United States|Australia|Austria|Canada|Denmark|France|Germany|Hong Kong|Italy|Korea, Republic of|Luxembourg|Netherlands|Norway|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Austria|Canada|France|Italy|Spain|Switzerland 1
United States|Australia|Belarus|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Poland|Russian Federation|Serbia|Slovenia|Spain|Ukraine 1
United States|Australia|Belgium|Bosnia and Herzegovina|Bulgaria|Canada|France|Georgia|Germany|Hong Kong|Italy|Japan|Netherlands|Singapore|Slovenia|Spain|Switzerland|Turkey|United Kingdom 1
United States|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|China|Colombia|Croatia|Cyprus|Czechia|Denmark|Estonia|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Lebanon|Lithuania|Netherlands|New Zealand|Peru|Poland|Portugal|Romania|Russian Federation|Serbia|Singapore|Slovakia|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Australia|Belgium|Canada|Chile|France|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Peru|Poland|Singapore|Slovakia|South Africa|Spain|Taiwan|Thailand|Turkey|United Kingdom|Vietnam 1
United States|Australia|Belgium|Canada|China|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|Puerto Rico|Romania|Russian Federation|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Singapore|Spain|Switzerland|Taiwan 1
United States|Australia|Belgium|Canada|France|Germany|Hungary|Italy|Japan|Korea, Republic of|Netherlands|Russian Federation|Spain|Switzerland|Taiwan|Thailand|Vietnam 1
United States|Australia|Belgium|Canada|France|Germany|Ireland|Italy|Poland|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|France|Hong Kong|Italy|Japan|Korea, Republic of|New Zealand|Norway|Russian Federation|Singapore|Spain|Sweden|Taiwan|Thailand|United Kingdom 1
United States|Australia|Belgium|Canada|Germany|Spain 1
United States|Australia|Belgium|Canada|Greece|Spain 1
United States|Australia|Belgium|Canada|Hong Kong|Italy|Netherlands|Singapore|Spain 1
United States|Australia|Belgium|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Poland|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Croatia|Poland|Romania|Russian Federation 1
United States|Australia|Belgium|Denmark|France|Germany|Italy|Korea, Republic of|Luxembourg|Netherlands|Russian Federation|Singapore|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Belgium|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Romania|Russian Federation|Spain|Taiwan|Ukraine 1
United States|Australia|Belgium|France|Germany|Italy|Korea, Republic of|Poland|Spain|Sweden 1
United States|Australia|Belgium|France|Italy|Korea, Republic of|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Greece|Japan|Korea, Republic of|Netherlands 1
United States|Australia|Bosnia and Herzegovina|Brazil|Canada|Chile|China|Costa Rica|Egypt|France|Germany|Guatemala|Hong Kong|Israel|Italy|Korea, Republic of|Mexico|New Zealand|Poland|Portugal|Russian Federation|Serbia|Singapore|Spain|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Australia|Brazil|Bulgaria|Chile|Croatia|Czechia|France|Germany|Greece|Hungary|India|Italy|Japan|Korea, Republic of|Malaysia|Netherlands|Philippines|Poland|Romania|Russian Federation|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine 1
United States|Australia|Brazil|Canada|China|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Mexico|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Brazil|Canada|Hong Kong|Korea, Republic of|Poland|Puerto Rico|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Brazil|Czech Republic|Russian Federation|Singapore 1
United States|Australia|Brazil|France|Bulgaria|Canada|China|Hungary|Italy|Japan|Korea, Republic of|Netherlands|New Zealand|Poland|Romania|Singapore|Spain|Taiwan|Ukraine 1
United States|Australia|Bulgaria 1
United States|Australia|Canada|China|Colombia|Estonia|France|Hungary|Israel|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Poland|Russian Federation|Taiwan|Turkey|Ukraine 1
United States|Australia|Canada|China|France|Italy|Japan|Korea, Republic of|Spain|Taiwan|United Kingdom 1
United States|Australia|Canada|Colombia|France|Hungary|Israel|Italy|Japan|Korea, Republic of|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Australia|Canada|Czech Republic|France|Greece|Hungary|Israel|Poland|Russian Federation|United Kingdom 1
United States|Australia|Canada|Czechia|France|Germany|Greece|Italy|Netherlands|United Kingdom 1
United States|Australia|Canada|Czechia|Hungary|Italy|Spain|United Kingdom 1
United States|Australia|Canada|Denmark|Estonia|Ireland|Israel|Italy|Japan|Korea, Republic of|Malaysia|Poland|Russian Federation|Spain|Switzerland|Turkey|Ukraine|United Kingdom 1
United States|Australia|Canada|Denmark|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Singapore|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Canada|Finland|France|Germany|Italy|Norway|Poland|Spain|Sweden 1
United States|Australia|Canada|France|Germany|Italy|Korea, Republic of|Norway|Singapore|Spain|Taiwan 1
United States|Australia|Canada|Hong Kong|Ireland|Italy|Japan|Korea, Republic of|Poland|Russian Federation|Singapore|South Africa|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Canada|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Russian Federation|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Canada|Hungary|Italy|Korea, Republic of|Poland|Taiwan|United Kingdom 1
United States|Australia|Canada|Israel|Korea, Republic of 1
United States|Australia|Chile|Croatia|France|Germany|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Serbia|Ukraine 1
United States|Australia|China 1
United States|Australia|China|Hungary|Korea, Republic of|Netherlands|Poland|Russian Federation|Taiwan|Thailand|Turkey|Vietnam 1
United States|Australia|Czech Republic|France|Germany|Hungary|Poland 1
United States|Australia|France|Germany|Hungary|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Spain|Taiwan|Ukraine 1
United States|Australia|France|Germany|Italy|Japan|Korea, Republic of|Spain|Taiwan|United Kingdom 1
United States|Australia|France|Germany|Italy|Netherlands|Singapore|Spain|Switzerland 1
United States|Australia|France|Germany|Korea, Republic of|New Zealand|Poland|Russian Federation|Spain|United Kingdom 1
United States|Australia|France|Germany|Korea, Republic of|Spain|Taiwan 1
United States|Australia|France|Israel|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|France|Italy|Japan 1
United States|Australia|Germany 1
United States|Australia|Germany|Italy|United Kingdom 1
United States|Australia|Hong Kong|Korea, Republic of|Singapore|Taiwan 1
United States|Australia|Hungary|Israel|Poland|Russian Federation|United Kingdom 1
United States|Australia|Italy|Singapore|Spain 1
United States|Australia|Japan|Korea, Republic of|Spain 1
United States|Australia|New Zealand|Poland|Thailand 1
United States|Australia|Puerto Rico|South Africa 1
United States|Australia|Spain|United Kingdom 1
United States|Austria|Belgium|Bulgaria|Germany|Hungary|Israel|Italy|Lithuania|Romania|Slovenia|Ukraine|United Kingdom 1
United States|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Italy|Japan|Korea, Republic of|Philippines|Poland|Singapore|Spain|Taiwan|Thailand|United Kingdom 1
United States|Austria|Belgium|Canada|Czechia|France|Germany|Italy|Netherlands|Poland|Spain|Switzerland 1
United States|Austria|Belgium|Canada|Finland|France|Germany|Italy|Netherlands|Poland|Portugal|Spain|Switzerland|United Kingdom 1
United States|Austria|Belgium|China|Denmark|Finland|France|Germany|Greece|Hungary|India|Ireland|Japan|Korea, Republic of|Mexico|Poland|Russian Federation|Slovakia|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
United States|Austria|Belgium|China|Greece|Korea, Republic of|Portugal|Spain|Ukraine 1
United States|Austria|Belgium|France|Germany|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Spain|Switzerland|Taiwan 1
United States|Austria|Canada|France|Germany|Israel|Italy|Poland|Spain 1
United States|Austria|Canada|France|Germany|Israel|Korea, Republic of 1
United States|Austria|Canada|France|Germany|Spain 1
United States|Austria|Canada|Germany|Hungary|Ireland|Italy|Portugal 1
United States|Austria|China|Czechia|France|Georgia|Greece|Ireland|Italy|Korea, Republic of|Lithuania|Malaysia|Poland|Romania|Russian Federation|Slovakia|Thailand|Ukraine 1
United States|Belgium|Brazil|Bulgaria|Canada|Czechia|France|Hungary|Italy|Mexico|Peru|Spain 1
United States|Belgium|Canada|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|Thailand|United Kingdom 1
United States|Belgium|Canada|Czechia|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain 1
United States|Belgium|Canada|France|Germany|Hong Kong|Ireland|Israel|Italy|Japan|Korea, Republic of|Lebanon|Netherlands|Portugal|Russian Federation|Singapore|Spain|Switzerland|Turkey|United Kingdom 1
United States|Belgium|Canada|France|Germany|Israel|Italy|Spain 1
United States|Belgium|Canada|France|Germany|Italy|Korea, Republic of|Poland|Spain|Sweden|Thailand|Turkey|United Kingdom 1
United States|Belgium|Canada|France|Israel|Italy|Netherlands|Spain 1
United States|Belgium|Canada|France|Italy|Poland|Spain|United Kingdom 1
United States|Belgium|Canada|Germany|Poland|United Kingdom 1
United States|Belgium|Canada|Spain 1
United States|Belgium|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|United Kingdom 1
United States|Belgium|China|France|Germany|Hong Kong|Japan|Korea, Republic of|Malaysia|Netherlands|Russian Federation|Singapore|Spain|Taiwan|Thailand|Vietnam 1
United States|Belgium|Denmark|France|Hungary 1
United States|Belgium|France 1
United States|Belgium|France|Germany|Greece|Israel|Netherlands|Spain 1
United States|Belgium|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Spain|United Kingdom 1
United States|Belgium|France|Germany|Italy|Netherlands|Romania|Spain 1
United States|Belgium|France|Germany|Korea, Republic of|Poland|Spain|Taiwan|United Kingdom 1
United States|Belgium|France|Italy|Spain|Taiwan|Turkey 1
United States|Belgium|France|Korea, Republic of|Spain 1
United States|Belgium|France|Netherlands|United Kingdom 1
United States|Belgium|Germany|Israel|Italy|Netherlands|Poland|Spain|United Kingdom 1
United States|Belgium|Germany|Italy|Poland|United Kingdom 1
United States|Belgium|Korea, Republic of|Netherlands|Taiwan|United Kingdom 1
United States|Belgium|United Kingdom 1
United States|Brazil 1
United States|Brazil|Bulgaria|Canada|China|Czech Republic|France|Hungary|Italy|Korea, Republic of|Latvia|Lithuania|Netherlands|Poland|Romania|Slovakia|South Africa|Taiwan|Thailand|Ukraine 1
United States|Brazil|Bulgaria|China|Germany|Hong Kong|Hungary|Japan|Korea, Republic of|Mexico|Peru|Poland|Russian Federation|South Africa|Taiwan|Thailand|Ukraine|United Kingdom|Vietnam 1
United States|Brazil|Bulgaria|France|Germany|Hungary|Netherlands|Poland 1
United States|Brazil|China|France|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Poland|Romania|Russian Federation|Serbia|Spain|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Bulgaria|Hungary|Russian Federation|Serbia 1
United States|Bulgaria|Romania 1
United States|Canada|Chile 1
United States|Canada|China|France|Hong Kong|Japan|Korea, Republic of|Singapore|Spain|Taiwan 1
United States|Canada|Czech Republic|Korea, Republic of|United Kingdom 1
United States|Canada|Denmark|France|Russian Federation 1
United States|Canada|France 1
United States|Canada|France|Germany|Greece|Hong Kong|Italy|Japan|Korea, Republic of|Romania|Spain|Taiwan|Turkey|United Kingdom 1
United States|Canada|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain|United Kingdom 1
United States|Canada|France|Germany|Hungary|Japan|Poland 1
United States|Canada|France|Germany|Hungary|Spain 1
United States|Canada|France|Germany|Korea, Republic of|Netherlands|Norway|Singapore|Spain|Turkey 1
United States|Canada|France|Hong Kong|Italy|Poland|Portugal|Spain|Taiwan 1
United States|Canada|France|Italy|Portugal|Spain|Switzerland 1
United States|Canada|France|Korea, Republic of|Spain 1
United States|Canada|France|Mexico|Netherlands|Spain|Taiwan 1
United States|Canada|France|Singapore|Taiwan 1
United States|Canada|Germany 1
United States|Canada|Germany|Israel|Italy|Spain 1
United States|Canada|Germany|Israel|Netherlands|Spain 1
United States|Canada|Germany|Japan|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan 1
United States|Canada|Hong Kong 1
United States|Canada|Hong Kong|Italy|Japan|Korea, Republic of|Spain|Taiwan 1
United States|Canada|Hong Kong|Korea, Republic of|Singapore|Thailand 1
United States|Canada|Hungary|India|Netherlands|Poland|Serbia|United Kingdom 1
United States|Canada|Hungary|Israel|Spain 1
United States|Canada|Hungary|Italy|Netherlands|Poland|Romania|Spain 1
United States|Canada|Hungary|Poland|Russian Federation|Slovakia 1
United States|Canada|Ireland|Peru|South Africa 1
United States|Canada|Israel 1
United States|Canada|Israel|Italy|Poland|Romania|Russian Federation|Serbia|Spain|Switzerland|Ukraine|United Kingdom 1
United States|Canada|Italy|Spain 1
United States|Canada|Japan|Korea, Republic of|Poland|Russian Federation|Taiwan|Ukraine 1
United States|Canada|Poland 1
United States|Canada|Poland|Portugal|Spain|United Kingdom 1
United States|Canada|Saudi Arabia 1
United States|Canada|Switzerland 1
United States|Chile|Argentina|Australia|Brazil|Germany|Italy|United Kingdom 1
United States|China|Argentina|Australia|Canada|Chile|France|Germany|Israel|Japan|Korea, Republic of|New Zealand|Poland|Russian Federation|Spain|Turkey|United Kingdom 1
United States|China|Germany|Italy|Japan|Korea, Republic of|Spain|Taiwan|United Kingdom 1
United States|Czech Republic|France|Poland|Spain|United Kingdom 1
United States|Czech Republic|Greece|Hungary|Netherlands|Slovakia 1
United States|Czech Republic|Hungary 1
United States|Czechia|France|Germany|Hungary|Israel|Italy|Poland|Spain|United Kingdom 1
United States|Denmark|Japan|Korea, Republic of|Netherlands|Norway|Spain|Sweden 1
United States|Denmark|Russian Federation 1
United States|Estonia|France|Germany|Japan|Korea, Republic of|Poland|Russian Federation|United Kingdom 1
United States|Finland|France|Germany|India|Italy|South Africa|Spain|Thailand 1
United States|France|Germany|Greece|Hungary|Japan|Netherlands|Russian Federation|Spain|Taiwan|Turkey 1
United States|France|Germany|Greece|Italy|Spain 1
United States|France|Germany|Italy 1
United States|France|Germany|Italy|Japan|Korea, Republic of|Netherlands|Norway|Spain|Taiwan|United Kingdom 1
United States|France|Germany|Italy|Korea, Republic of|Portugal 1
United States|France|Germany|Italy|Spain|United Kingdom 1
United States|France|Germany|Japan|Korea, Republic of|Malaysia|Spain|Taiwan 1
United States|France|Germany|Japan|Spain|United Kingdom 1
United States|France|Germany|Spain 1
United States|France|Greece|Hungary|Italy|Korea, Republic of|Netherlands|Spain 1
United States|France|Hong Kong|Korea, Republic of|Spain|United Kingdom 1
United States|France|Israel|Japan|United Kingdom 1
United States|France|Israel|Luxembourg|Spain 1
United States|France|Israel|Spain|Taiwan 1
United States|France|Italy|Korea, Republic of|Spain|Taiwan 1
United States|France|Italy|Spain 1
United States|France|Italy|Taiwan|United Kingdom 1
United States|France|Japan|Netherlands|Spain 1
United States|France|Japan|Spain 1
United States|France|Korea, Republic of|Serbia|Spain|Taiwan 1
United States|France|Korea, Republic of|Spain|Taiwan 1
United States|France|Korea, Republic of|Spain|Turkey 1
United States|France|Netherlands 1
United States|France|Netherlands|Spain 1
United States|France|Spain 1
United States|Germany|Argentina|Austria|Belgium|Brazil|Canada|Chile|Colombia|Czech Republic|Denmark|Greece|Hong Kong|Hungary|Italy|Korea, Republic of|Netherlands|Norway|Poland|Russian Federation|Slovakia|Spain|Switzerland|Taiwan|Thailand|United Kingdom 1
United States|Germany|Australia|Belgium|Canada|China|France|Hong Kong|Hungary|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Portugal|Romania|Russian Federation|Spain|Taiwan|Ukraine|United Kingdom 1
United States|Germany|Hong Kong|Japan 1
United States|Germany|Hungary|Romania 1
United States|Germany|India|Korea, Republic of 1
United States|Germany|Italy|Korea, Republic of|Poland|Spain|Switzerland 1
United States|Germany|Italy|Spain|United Kingdom 1
United States|Germany|Japan|Korea, Republic of|Puerto Rico 1
United States|Germany|Korea, Republic of|Mexico|Poland|Russian Federation 1
United States|Germany|Korea, Republic of|Netherlands|Spain|Taiwan|United Kingdom 1
United States|Germany|Latvia|Poland|Russian Federation|Ukraine 1
United States|Germany|Puerto Rico 1
United States|Hong Kong|Korea, Republic of|Malaysia|Singapore|Taiwan|Thailand 1
United States|Hong Kong|Korea, Republic of|Singapore|Taiwan 1
United States|Hong Kong|Netherlands|Singapore|Taiwan 1
United States|Hungary|Italy|Korea, Republic of|Poland|Russian Federation|Spain|Taiwan 1
United States|Hungary|Korea, Republic of|Romania|Russian Federation|Taiwan 1
United States|Hungary|Poland|Russian Federation 1
United States|India|Poland|Romania 1
United States|India|United Kingdom 1
United States|Israel|Japan|Spain 1
United States|Israel|Spain 1
United States|Italy|Argentina|Australia|Austria|Belgium|Brazil|Canada|China|Czech Republic|Denmark|France|Germany|Greece|Hong Kong|Hungary|India|Ireland|Israel|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Romania|Russian Federation|Singapore|Slovakia|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Italy|Japan|Poland|Romania|Russian Federation|Spain|Switzerland|Taiwan|Ukraine|United Kingdom 1
United States|Italy|Korea, Republic of|Malaysia|Spain 1
United States|Italy|Korea, Republic of|Spain 1
United States|Italy|Korea, Republic of|Taiwan 1
United States|Italy|Lithuania 1
United States|Italy|Spain 1
United States|Japan|Korea, Republic of 1
United States|Japan|Korea, Republic of|Spain|Taiwan 1
United States|Japan|Netherlands|Spain|Taiwan 1
United States|Korea, Republic of|Netherlands|Spain|Taiwan|United Kingdom 1
United States|Korea, Republic of|Spain|Taiwan 1
United States|Korea, Republic of|Taiwan 1
United States|Norway|United Kingdom 1
United States|Puerto Rico|South Africa 1
United States|Russian Federation|Ukraine 1
United States|South Africa 1
United States|Switzerland 1

Sites per Study

Site_count Study_Count
1 918
2 165
3 88
4 80
5 75
6 33
7 56
8 39
9 35
10 38
11 29
12 33
13 30
14 18
15 24
16 28
17 15
18 12
19 19
20 21
21 18
22 12
23 11
24 14
25 13
26 10
27 7
28 9
29 7
30 14
31 9
32 9
33 11
34 4
35 8
36 6
37 8
38 10
39 4
40 5
41 3
42 10
43 4
44 11
45 3
46 4
47 8
48 3
49 1
50 5
51 4
52 7
53 2
54 2
55 2
56 4
57 3
58 2
59 5
60 6
61 1
62 2
63 1
64 3
65 4
66 2
67 2
68 2
69 7
70 3
71 4
72 4
73 3
74 4
75 2
76 2
77 1
78 3
79 3
80 2
81 1
82 1
84 5
85 3
86 3
87 2
88 2
89 1
90 3
91 3
92 3
93 4
94 3
96 1
97 1
98 1
99 1
101 4
103 1
105 3
108 1
109 1
110 3
111 1
112 1
113 2
114 2
115 2
116 1
117 3
118 2
119 1
120 2
121 1
122 1
123 4
124 2
125 1
126 1
127 1
129 1
132 1
133 5
134 1
135 2
136 1
137 1
139 1
140 1
141 4
143 2
144 1
145 1
147 2
148 1
150 1
152 1
153 1
154 3
155 3
156 1
157 2
158 1
160 1
161 1
162 2
163 1
166 1
167 2
168 1
170 1
175 1
179 1
181 1
182 3
183 1
185 1
186 1
187 1
188 2
189 2
192 1
196 1
197 1
199 1
200 1
204 1
207 1
208 1
210 2
212 1
213 2
216 1
224 2
227 1
228 1
230 1
231 2
233 1
237 1
240 2
242 1
247 2
248 1
249 1
257 1
260 1
263 1
264 2
271 1
279 1
287 1
295 2
301 1
305 1
332 1
339 1
348 1
369 2
386 1
418 1
457 1
468 1
484 1
532 1
544 1
605 1
638 1
658 1
743 1
873 1
892 1
931 1
1175 1
1498 2

Phase

Phase Study_Count
Phase 2 1017
Phase 1 423
Phase 3 359
Phase 1/Phase 2 228
N/A 180
Phase 4 43
Phase 2/Phase 3 28
Early Phase 1 16

Number of Arms

Number_of_Arms Count_of_Studies
1 945
2 798
3 151
4 81
5 22
6 18
7 11
8 5
9 8
10 5
11 2
12 1
13 1
14 2
15 1
16 1
18 2
19 1
24 1
NA 238

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 3.0 3.0000 1.00000 2.0000 1.00000 40.0000 1.000 5.0000
1st Qu. 12.0 29.0000 18.00000 40.0000 40.00000 116.0000 275.750 53.0000
Median 22.5 58.0000 31.00000 70.0000 65.00000 187.0000 453.500 107.5000
Mean 32.5 443.8371 60.51074 103.5946 97.38641 634.7857 550.321 384.6905
3rd Qu. 32.0 150.7500 56.50000 122.5000 120.00000 409.7500 671.500 195.0000
Max. 180.0 39981.0000 1260.00000 970.0000 1805.00000 10000.0000 5000.000 6586.0000

Trial Group Type

group_type Group_Count
Experimental 3086
Active Comparator 560
NA 238
Placebo Comparator 167
Other 99
No Intervention 45
Sham Comparator 3

Intervention Model

intervention_model Study_Count
Single Group Assignment 1113
Parallel Assignment 997
NA 93
Sequential Assignment 58
Crossover Assignment 27
Factorial Assignment 6

Primary Purpose

primary_purpose Study_Count
Treatment 2123
Diagnostic 61
Supportive Care 34
Other 30
Prevention 14
Basic Science 11
NA 8
Health Services Research 6
Screening 6
Device Feasibility 1

Observational Studies

Studies by Country

Country Study_Count
China 58
United States 54
France 29
NA 19
Germany 12
Netherlands 11
Spain 10
Korea, Republic of 9
Japan 8
Taiwan 8
Canada 7
Belgium 5
Denmark 5
Italy 5
United Kingdom 5
Greece 4
United States|Canada 4
Austria 3
Mexico 3
Poland 3
Singapore 3
Brazil 2
Egypt 2
Ireland 2
Russian Federation 2
Argentina 1
Argentina|Chile|Colombia|Dominican Republic|India|Mexico|Peru|Taiwan|Thailand|Uruguay 1
Argentina|Chile|Colombia|Uruguay 1
Australia 1
Australia|Belgium|France|Germany|Israel|Italy|Netherlands|Norway|Switzerland|United Kingdom 1
Australia|New Zealand|Singapore 1
Austria|Belgium|Denmark|Germany|Greece|Hungary|Italy|Lithuania|Luxembourg|Netherlands|Spain|Sweden|United Kingdom 1
Austria|Belgium|Germany|Spain|Switzerland 1
Austria|Germany 1
Bahrain|Qatar|United Arab Emirates 1
Belgium|France|Germany|Greece|Italy|Portugal|Spain|Turkey 1
China|Japan|Korea, Republic of 1
Czechia|Germany|Poland|Spain|Switzerland|United Kingdom 1
Egypt|Lebanon|Morocco|Saudi Arabia|United Arab Emirates 1
Finland 1
Hong Kong|Korea, Republic of|Malaysia|Singapore 1
Hungary 1
India 1
Jordan 1
Kazakhstan 1
Korea, Republic of|Singapore 1
Norway 1
Serbia 1
Sweden 1
United States|Austria|Canada|France|Germany|Italy|Japan|Korea, Republic of|Mexico|Poland|Singapore|Spain|Taiwan 1
United States|Bolivia|Mexico|Peru|Venezuela 1
United States|Denmark 1

Sites per Study

Site_count Study_Count
1 176
2 8
3 8
4 7
5 9
6 5
7 3
8 3
9 5
10 9
11 5
12 2
13 1
14 4
15 2
17 2
18 1
21 1
22 2
23 4
24 2
25 1
26 2
28 1
29 2
31 2
32 2
33 2
35 1
37 1
39 1
41 1
42 1
43 1
44 1
46 1
50 1
56 1
61 1
63 1
71 1
72 1
73 1
81 1
88 1
92 1
101 1
111 1
118 1
120 1
133 1
152 1
170 1
198 1
299 1
405 1
432 1

Enrollment Metrics

Measure Observational
Min 1.0000
1st Qu 70.0000
Median 165.0000
Mean 782.3345
3rd Qu 503.2500
Max 50000.0000

Observation Model

observational_model Study_Count
Cohort 188
Case-Only 66
Other 17
NA 10
Case-Control 9
Case Control 6
Case-Crossover 2
Defined Population 1
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 188
Retrospective 87
Cross-Sectional 14
Other 7
NA 3
Longitudinal, Prospective 1

Registries

Studies by Country

Country Study_Count
China 7
Korea, Republic of 3
Belgium 2
Germany 2
Greece 2
Japan 2
NA 2
Denmark|Norway 1
Egypt 1
France 1
Netherlands 1
United Kingdom 1
United States 1

Sites per Study

Site_count Study_Count
1 19
2 1
5 1
8 1
34 1
44 2
73 1

Enrollment Metrics

Measure Registries
Min 20.000
1st Qu 132.000
Median 315.000
Mean 1034.808
3rd Qu 989.000
Max 7500.000

Registry Model

observational_model Study_Count
Cohort 20
Other 4
Case-Only 2

Time Perspective

time_perspective Study_Count
Prospective 21
Other 5

Follow-up

target_duration Study_Count
3 Years 11
5 Years 4
1 Year 2
24 Months 2
1 Day 1
12 Months 1
2 Years 1
20 Months 1
36 Months 1
4 Months 1
7 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04455984 Multimodality Treatment Including Curative Resection of Advanced NSCLC https://ClinicalTrials.gov/show/NCT04455984 Recruiting Medical University of Vienna 2020-08-01
NCT04165798 Umbrella Master Protocol: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYNOTE-U01) https://ClinicalTrials.gov/show/NCT04165798 Recruiting Merck Sharp & Dohme Corp. 2032-02-13
NCT03389399 Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases https://ClinicalTrials.gov/show/NCT03389399 Recruiting University of Colorado, Denver 2021-08-30
NCT03375242 Safety and Efficacy of Xalkori ROS1 https://ClinicalTrials.gov/show/NCT03375242 Recruiting Pfizer 2022-03-14
NCT03373955 A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients https://ClinicalTrials.gov/show/NCT03373955 Recruiting Sichuan University 2020-07-31
NCT03370770 Afatinib Osimertinib Sequencing NIS https://ClinicalTrials.gov/show/NCT03370770 Completed Boehringer Ingelheim 2019-11-28
NCT03816657 The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT03816657 Active, not recruiting Fondazione Ricerca Traslazionale 2017-05-15
NCT03363685 Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis https://ClinicalTrials.gov/show/NCT03363685 Recruiting Ruijin Hospital 2022-11-01
NCT03289780 Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects https://ClinicalTrials.gov/show/NCT03289780 Recruiting Biodesix, Inc. 2019-06-30
NCT03273790 A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan https://ClinicalTrials.gov/show/NCT03273790 Active, not recruiting Bristol-Myers Squibb 2019-10-31
NCT03271554 Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea https://ClinicalTrials.gov/show/NCT03271554 Recruiting Hoffmann-La Roche 2021-12-31
NCT03258788 A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03258788 Recruiting The Christie NHS Foundation Trust 2019-12-31
NCT03236675 Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients https://ClinicalTrials.gov/show/NCT03236675 Active, not recruiting Exosome Diagnostics, Inc. 2020-02-29
NCT03219970 Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting. https://ClinicalTrials.gov/show/NCT03219970 Active, not recruiting AstraZeneca 2020-05-31
NCT03216551 Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC https://ClinicalTrials.gov/show/NCT03216551 Recruiting Fudan University 2021-04-01
NCT03199599 Prognostic PET/CT Model in Non Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03199599 Completed Poitiers University Hospital 2019-08-31
NCT03170284 Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03170284 Completed Hoffmann-La Roche 2012-08-01
NCT03137264 Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients https://ClinicalTrials.gov/show/NCT03137264 Completed AstraZeneca 2018-11-10
NCT03141957 Hypermetabolism in the Elderly Lung Cancer Patient https://ClinicalTrials.gov/show/NCT03141957 Completed University of Paris 5 - Rene Descartes 2016-11-30
NCT03132493 Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient https://ClinicalTrials.gov/show/NCT03132493 Completed Spanish Lung Cancer Group 2017-12-01
NCT03133234 Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC https://ClinicalTrials.gov/show/NCT03133234 Completed AstraZeneca 2017-09-13
NCT03130192 A Study of the Correlation Between CRF, Survival and Physiological Factors in NSCLC Patients Under Chemotherapy https://ClinicalTrials.gov/show/NCT03130192 Recruiting Chung Shan Medical University 2021-06-07
NCT03092739 A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens https://ClinicalTrials.gov/show/NCT03092739 Completed Hoffmann-La Roche 2018-01-08
NCT03059641 Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China https://ClinicalTrials.gov/show/NCT03059641 Completed Geneplus-Beijing Co. Ltd. 2019-12-31
NCT03055715 Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC https://ClinicalTrials.gov/show/NCT03055715 Completed Martin-Luther-Universität Halle-Wittenberg 2018-04-01
NCT03042221 Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy https://ClinicalTrials.gov/show/NCT03042221 Recruiting University of Colorado, Denver 2020-09-30
NCT03037086 Asia PDL1 Study Among NSCLC Patients https://ClinicalTrials.gov/show/NCT03037086 Completed AstraZeneca 2017-02-27
NCT02980536 cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China https://ClinicalTrials.gov/show/NCT02980536 Active, not recruiting Berry Genomics Co., Ltd. 2018-10-31
NCT02972216 Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy https://ClinicalTrials.gov/show/NCT02972216 Completed Yung Shin Pharm. Ind. Co., Ltd. 2016-10-31
NCT02968979 Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer. https://ClinicalTrials.gov/show/NCT02968979 Completed Chugai Pharma France 2016-10-31
NCT02966769 N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation https://ClinicalTrials.gov/show/NCT02966769 Completed Grupo de Investigación Clínica en Oncología Radioterapia 2017-03-31
NCT03232593 A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) https://ClinicalTrials.gov/show/NCT03232593 Recruiting Hoffmann-La Roche 2023-01-11
NCT02932345 Gefitinib Long-term Survivor Study https://ClinicalTrials.gov/show/NCT02932345 Completed AstraZeneca 2017-07-04
NCT02933346 Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program https://ClinicalTrials.gov/show/NCT02933346 Active, not recruiting Intergroupe Francophone de Cancerologie Thoracique 2018-01-31
NCT02910999 Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy https://ClinicalTrials.gov/show/NCT02910999 Active, not recruiting Bristol-Myers Squibb 2023-12-31
NCT02906852 Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing https://ClinicalTrials.gov/show/NCT02906852 Completed Inivata 2018-05-31
NCT02848872 Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02848872 Completed Duke University 2019-04-02
NCT02827344 PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02827344 Recruiting University Hospital, Toulouse 2019-10-31
NCT02799862 Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC https://ClinicalTrials.gov/show/NCT02799862 Active, not recruiting iOMEDICO AG 2019-12-07
NCT02777567 KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy) https://ClinicalTrials.gov/show/NCT02777567 Completed AstraZeneca 2020-03-19
NCT02764606 CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02764606 Recruiting Hospices Civils de Lyon 2025-12-31
NCT02740894 Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ? https://ClinicalTrials.gov/show/NCT02740894 Completed Taipei Veterans General Hospital, Taiwan 2016-04-30
NCT02727335 Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements https://ClinicalTrials.gov/show/NCT02727335 Completed Intergroupe Francophone de Cancerologie Thoracique 2015-12-31
NCT02718651 Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer https://ClinicalTrials.gov/show/NCT02718651 Completed University of Aarhus 2018-12-31
NCT02714335 The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients https://ClinicalTrials.gov/show/NCT02714335 Completed National Taiwan University 2013-11-30
NCT02695849 A Study of Prevalence of EGFR Mutations in Participants With NSCLC https://ClinicalTrials.gov/show/NCT02695849 Completed Hoffmann-La Roche 2015-05-31
NCT02679170 Prospective Observational Study To Identify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) And ALK Translocation And To Establish Their Therapeutic Management (IDEALK) https://ClinicalTrials.gov/show/NCT02679170 Recruiting Pfizer 2020-06-30
NCT02671422 LUME BioNIS: a Biomarker Study in Patients With NSCLC https://ClinicalTrials.gov/show/NCT02671422 Completed Boehringer Ingelheim 2019-09-03
NCT02658747 Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK https://ClinicalTrials.gov/show/NCT02658747 Completed Hoffmann-La Roche 2016-07-25
NCT02645318 Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02645318 Completed Peking University People’s Hospital 2015-07-31
NCT02623257 EGFR Mutations on ctDNA in Patients With Advanced NSCLC https://ClinicalTrials.gov/show/NCT02623257 Completed First People’s Hospital of Hangzhou 2017-07-31
NCT02619929 Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria https://ClinicalTrials.gov/show/NCT02619929 Completed Pierre Fabre Pharma GmbH 2018-03-31
NCT02620657 Evaluate EGFR Mutation Status and Impact Factors in North China https://ClinicalTrials.gov/show/NCT02620657 Completed Guangdong Association of Clinical Trials 2017-11-08
NCT02595450 A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02595450 Completed Hoffmann-La Roche 2014-11-30
NCT02575560 Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT02575560 Completed Qingdao Central Hospital 2017-09-30
NCT02038413 State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients https://ClinicalTrials.gov/show/NCT02038413 Completed Maastricht Radiation Oncology 2014-10-31
NCT02146170 Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors https://ClinicalTrials.gov/show/NCT02146170 Recruiting National Institutes of Health Clinical Center (CC) 2024-04-30
NCT02321046 An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer). https://ClinicalTrials.gov/show/NCT02321046 Completed AstraZeneca 2019-06-28
NCT02511288 LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02511288 Recruiting Centre Leon Berard 2026-03-31
NCT02475720 Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC) https://ClinicalTrials.gov/show/NCT02475720 Completed AstraZeneca 2016-03-16
NCT02458651 Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China https://ClinicalTrials.gov/show/NCT02458651 Completed Hoffmann-La Roche 2018-10-30
NCT02445924 Micro RNA Genetic Signature in NSCLC Egyptian Patients https://ClinicalTrials.gov/show/NCT02445924 Completed Tanta University 2016-01-31
NCT02428049 Lung Function Changes After Curative Targeted Radiotherapy of Non-small-cell Lung Carcinoma https://ClinicalTrials.gov/show/NCT02428049 Recruiting Sykehuset i Vestfold HF 2018-12-31
NCT02418234 T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure https://ClinicalTrials.gov/show/NCT02418234 Completed First People’s Hospital of Hangzhou 2016-04-30
NCT02410603 Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer https://ClinicalTrials.gov/show/NCT02410603 Recruiting Mayo Clinic 2020-06-30
NCT02392455 VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT02392455 Recruiting Boehringer Ingelheim 2022-12-31
NCT02380196 The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02380196 Completed Abramson Cancer Center of the University of Pennsylvania 2019-12-31
NCT02370303 A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System https://ClinicalTrials.gov/show/NCT02370303 Completed Mayo Clinic 2016-07-09
NCT02338583 Powered Surgical Stapler in VATS Lung Resection Procedures in China https://ClinicalTrials.gov/show/NCT02338583 Completed Ethicon Endo-Surgery 2015-04-01
NCT02304406 Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa https://ClinicalTrials.gov/show/NCT02304406 Completed Pfizer 2018-02-11
NCT02293733 Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) https://ClinicalTrials.gov/show/NCT02293733 Completed Groupe Francais De Pneumo-Cancerologie 2014-03-31
NCT02285361 GIOTRIF rPMS in Korean Patients With NSCLC https://ClinicalTrials.gov/show/NCT02285361 Completed Boehringer Ingelheim 2019-12-31
NCT02271581 Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer https://ClinicalTrials.gov/show/NCT02271581 Recruiting Leo W. Jenkins Cancer Center 2020-07-31
NCT02245100 Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02245100 Recruiting Thomas Jefferson University 2020-07-31
NCT02196675 Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea https://ClinicalTrials.gov/show/NCT02196675 Completed Ethicon Endo-Surgery 2015-01-31
NCT02169349 Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02169349 Completed Rennes University Hospital 2016-06-30
NCT02171286 The Oncopanel Pilot (TOP) Study https://ClinicalTrials.gov/show/NCT02171286 Completed British Columbia Cancer Agency 2017-03-31
NCT02133508 A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib) https://ClinicalTrials.gov/show/NCT02133508 Completed Hoffmann-La Roche 2016-06-10
NCT02131259 Long-term Observation PMS for Afatinib https://ClinicalTrials.gov/show/NCT02131259 Completed Boehringer Ingelheim 2016-12-28
NCT02109549 Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients. https://ClinicalTrials.gov/show/NCT02109549 Completed Maastricht Radiation Oncology 2015-12-31
NCT01300429 Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus https://ClinicalTrials.gov/show/NCT01300429 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-02-28
NCT01290809 Prophylactic Cranial Irradiation (PCI) Cognitive Tests in Non-small Cell Lung Cancer (NSCLC) Patients https://ClinicalTrials.gov/show/NCT01290809 Completed Maastricht Radiation Oncology 2015-03-31
NCT01294280 Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy https://ClinicalTrials.gov/show/NCT01294280 Recruiting Alliance for Clinical Trials in Oncology 2100-01-31
NCT01279408 Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC) https://ClinicalTrials.gov/show/NCT01279408 Active, not recruiting University Health Network, Toronto 2028-11-30
NCT02047903 GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations https://ClinicalTrials.gov/show/NCT02047903 Completed Boehringer Ingelheim 2018-12-31
NCT02042105 A Prospective Epidemiologic Study of ALK-Positive NSCLC in China https://ClinicalTrials.gov/show/NCT02042105 Completed Guangdong Association of Clinical Trials 2015-04-15
NCT01991418 Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC) https://ClinicalTrials.gov/show/NCT01991418 Completed Hunan Province Tumor Hospital 2016-02-29
NCT01994057 A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib and Erlotinib, in NSCLC Patients Treatment https://ClinicalTrials.gov/show/NCT01994057 Recruiting Sun Yat-sen University 2021-10-31
NCT01985113 Correlation Research of Thioredoxin Reductase in Lung Cancer https://ClinicalTrials.gov/show/NCT01985113 Completed Hunan Province Tumor Hospital 2016-02-29
NCT01980212 Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01980212 Completed Hunan Province Tumor Hospital 2016-12-01
NCT01956331 Comprehensive Geriatric Assessment and Complications Following Lung Resection for Lung Cancer https://ClinicalTrials.gov/show/NCT01956331 Completed Groupe Francais De Pneumo-Cancerologie 2013-06-30
NCT01947868 Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor https://ClinicalTrials.gov/show/NCT01947868 Completed AstraZeneca 2015-09-30
NCT01941303 Analysis of Treatment Outcome and Toxicity in Non-small Cell Lung Cancer Patients Wither-irradiated to a High Dose for Recurrent Disease https://ClinicalTrials.gov/show/NCT01941303 Completed Maastricht Radiation Oncology 2015-09-30
NCT01934465 Bevacizumab Plus Chemotherapy for Advanced Non Small Cell Lung Cancer Patients as 1st Line Treatment https://ClinicalTrials.gov/show/NCT01934465 Completed Hellenic Oncology Research Group 2013-12-31
NCT01893268 An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice https://ClinicalTrials.gov/show/NCT01893268 Completed Hoffmann-La Roche 2018-03-20
NCT04351334 Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns https://ClinicalTrials.gov/show/NCT04351334 Active, not recruiting Pfizer 2020-07-31
NCT01888601 TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx) https://ClinicalTrials.gov/show/NCT01888601 Recruiting University College, London 2023-11-30
NCT01843192 Powered Echelon Device in VATS Surgery https://ClinicalTrials.gov/show/NCT01843192 Completed Ethicon Endo-Surgery 2014-05-31
NCT01837511 Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients https://ClinicalTrials.gov/show/NCT01837511 Completed GlaxoSmithKline 2008-01-31
NCT01837186 Empyema Following Pneumonectomy for Non Small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT01837186 Completed University Hospital, Gasthuisberg 2012-09-30
NCT01836133 An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT) https://ClinicalTrials.gov/show/NCT01836133 Completed Hoffmann-La Roche 2016-01-31
NCT01830426 Circulating Tumor Cells in Non-Small Cell Lung Carcinoma https://ClinicalTrials.gov/show/NCT01830426 Completed Epic Sciences 2015-12-31
NCT01790217 An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC) https://ClinicalTrials.gov/show/NCT01790217 Completed Hoffmann-La Roche 2013-08-31
NCT01795352 Retrospective Study in a NSCLC M+ p https://ClinicalTrials.gov/show/NCT01795352 Completed AstraZeneca 2013-10-31
NCT01772225 NSCLC Burden of Illness Study https://ClinicalTrials.gov/show/NCT01772225 Completed GlaxoSmithKline 2014-01-31
NCT01740804 Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC https://ClinicalTrials.gov/show/NCT01740804 Completed Guangdong Association of Clinical Trials 2016-04-30
NCT01726309 Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 https://ClinicalTrials.gov/show/NCT01726309 Active, not recruiting Cancer Trials Ireland 2024-08-31
NCT01723878 ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations https://ClinicalTrials.gov/show/NCT01723878 Completed Hoffmann-La Roche 2017-06-20
NCT01721252 Tarceva. ICORG 08-41 https://ClinicalTrials.gov/show/NCT01721252 Completed Cancer Trials Ireland 2013-08-31
NCT01700582 French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings https://ClinicalTrials.gov/show/NCT01700582 Completed Intergroupe Francophone de Cancerologie Thoracique 2013-04-30
NCT01662635 Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK) https://ClinicalTrials.gov/show/NCT01662635 Completed Instituto Nacional de Cancerologia de Mexico 2014-09-30
NCT01664533 An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy https://ClinicalTrials.gov/show/NCT01664533 Completed Hoffmann-La Roche 2013-08-31
NCT01659970 PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01659970 Completed Hoffmann-La Roche 2014-04-30
NCT01660776 BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology https://ClinicalTrials.gov/show/NCT01660776 Completed Rennes University Hospital 2017-10-02
NCT01630122 Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates https://ClinicalTrials.gov/show/NCT01630122 Completed Wake Forest University Health Sciences 2015-08-18
NCT01620853 Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test) https://ClinicalTrials.gov/show/NCT01620853 Completed Applied Spectral Imaging Ltd. 2013-01-31
NCT01598597 An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite) https://ClinicalTrials.gov/show/NCT01598597 Completed Genentech, Inc. 2014-11-30
NCT01597258 Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan) https://ClinicalTrials.gov/show/NCT01597258 Completed Pfizer 2018-03-16
NCT04018183 The Role of Protein Tyrosine Kinase 7 (PTK7) in Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT04018183 Completed National Taiwan University Hospital 2020-03-24
NCT01562665 Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf https://ClinicalTrials.gov/show/NCT01562665 Completed AstraZeneca 2015-02-28
NCT01551251 Tumor Associated Macrophage in Advanced Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01551251 Completed Chang Gung Memorial Hospital 2010-12-31
NCT01540045 Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01540045 Completed Instituto Nacional de Cancerologia de Mexico 2011-12-31
NCT01535729 An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01535729 Completed Hoffmann-La Roche 2014-06-30
NCT01525199 Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations. https://ClinicalTrials.gov/show/NCT01525199 Completed AstraZeneca 2013-11-30
NCT01512420 An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT) https://ClinicalTrials.gov/show/NCT01512420 Completed Hoffmann-La Roche 2015-02-28
NCT01510405 Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01510405 Active, not recruiting Dartmouth-Hitchcock Medical Center 2020-12-31
NCT01488331 An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01488331 Completed Hoffmann-La Roche 2013-11-30
NCT01482182 Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy https://ClinicalTrials.gov/show/NCT01482182 Completed Samsung Medical Center 2013-11-30
NCT01385722 Molecular Analysis of Thoracic Malignancies https://ClinicalTrials.gov/show/NCT01385722 Enrolling by invitation Stanford University 2031-06-30
NCT01358942 An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab) https://ClinicalTrials.gov/show/NCT01358942 Completed Hoffmann-La Roche 2012-11-30
NCT01346280 Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs https://ClinicalTrials.gov/show/NCT01346280 Completed National Institutes of Health Clinical Center (CC) NA
NCT01343914 An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy https://ClinicalTrials.gov/show/NCT01343914 Completed Hoffmann-La Roche 2011-12-31
NCT01333007 An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01333007 Completed Hoffmann-La Roche 2013-05-31
NCT04430725 Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study https://ClinicalTrials.gov/show/NCT04430725 Recruiting M.D. Anderson Cancer Center 2023-01-01
NCT04430712 Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume https://ClinicalTrials.gov/show/NCT04430712 Active, not recruiting Massachusetts General Hospital 2021-03-31
NCT04405661 Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC https://ClinicalTrials.gov/show/NCT04405661 Recruiting Guangzhou Institute of Respiratory Disease 2021-05-31
NCT04324164 Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC https://ClinicalTrials.gov/show/NCT04324164 Recruiting Hunan Province Tumor Hospital 2021-03-24
NCT04324151 Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC https://ClinicalTrials.gov/show/NCT04324151 Recruiting Hunan Province Tumor Hospital 2021-03-24
NCT04324125 Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC https://ClinicalTrials.gov/show/NCT04324125 Recruiting Hunan Province Tumor Hospital 2021-03-24
NCT04322890 PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene Mutation Positive Advanced NSCLC https://ClinicalTrials.gov/show/NCT04322890 Recruiting Hunan Province Tumor Hospital 2021-03-24
NCT04322617 Anlotinib Plus PD-1 Antibody in Standard Chemotherapy Failure Advanced NSCLC: the ATHENA Study https://ClinicalTrials.gov/show/NCT04322617 Recruiting Hunan Province Tumor Hospital 2021-03-24
NCT04322591 Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial https://ClinicalTrials.gov/show/NCT04322591 Recruiting Hunan Province Tumor Hospital 2021-03-24
NCT04322578 Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC https://ClinicalTrials.gov/show/NCT04322578 Recruiting Hunan Province Tumor Hospital 2021-03-24
NCT04317651 Crizotinib in ALK Rearranged Non-small-cell Lung Cancer https://ClinicalTrials.gov/show/NCT04317651 Recruiting Fondazione Ricerca Traslazionale 2021-12-31
NCT04309422 Texture Features and PDL1 in CT-PET 18 FDG https://ClinicalTrials.gov/show/NCT04309422 Completed University Hospital, Montpellier 2018-10-01
NCT04291755 Development and Analysis of a Stool Bank for Cancer Patients https://ClinicalTrials.gov/show/NCT04291755 Recruiting Persephone Biosciences 2020-12-31
NCT04257864 Bevacizumab Versus Docetaxel/Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT04257864 Completed Hellenic Cooperative Oncology Group 2010-05-31
NCT04238130 Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection https://ClinicalTrials.gov/show/NCT04238130 Recruiting Sun Yat-sen University 2022-12-18
NCT04207775 Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy https://ClinicalTrials.gov/show/NCT04207775 Recruiting AstraZeneca 2023-05-30
NCT04206787 The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer https://ClinicalTrials.gov/show/NCT04206787 Recruiting Boehringer Ingelheim 2023-12-15
NCT04208854 Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT04208854 Recruiting International Group of Endovascular Oncology 2020-04-18
NCT04197076 Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIIA https://ClinicalTrials.gov/show/NCT04197076 Recruiting Shanghai Chest Hospital 2021-05-01
NCT04189679 Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma https://ClinicalTrials.gov/show/NCT04189679 Recruiting University Hospital, Grenoble 2021-11-30
NCT04187768 Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT04187768 Recruiting Indiana University 2020-12-31
NCT04179890 The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib https://ClinicalTrials.gov/show/NCT04179890 Active, not recruiting Boehringer Ingelheim 2020-07-17
NCT04164186 Fully Automated Pipeline for the Detection and Segmentation of Non-Small Cell Lung Cancer (NSCLC) on CT Images https://ClinicalTrials.gov/show/NCT04164186 Active, not recruiting Maastricht University 2019-11-07
NCT04154163 Appropriate Dosing to Optimise Personalised Cancer Treatments https://ClinicalTrials.gov/show/NCT04154163 Recruiting University of Dundee 2020-07-30
NCT04151940 PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT04151940 Recruiting University of Washington 2021-06-01
NCT04145232 AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient’s Response to Immunotherapies. https://ClinicalTrials.gov/show/NCT04145232 Recruiting Ardigen 2020-06-30
NCT04136470 BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics https://ClinicalTrials.gov/show/NCT04136470 Recruiting Ardigen 2020-09-30
NCT04137718 Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation https://ClinicalTrials.gov/show/NCT04137718 Recruiting Shanghai Pulmonary Hospital, Shanghai, China 2022-10-20
NCT04116918 Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC https://ClinicalTrials.gov/show/NCT04116918 Recruiting Shanghai Changzheng Hospital 2021-09-30
NCT04087473 Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC https://ClinicalTrials.gov/show/NCT04087473 Recruiting National Cancer Centre, Singapore 2022-06-30
NCT04092465 Outcomes of Surgical Resection After Induction Treatment in Non-Small Cell Lung Cancer (SRaIT) https://ClinicalTrials.gov/show/NCT04092465 Completed AHEPA University Hospital 2019-08-31
NCT04076228 Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients https://ClinicalTrials.gov/show/NCT04076228 Recruiting Kiang Wu Hospital 2020-01-01
NCT04069663 Efficacy of Re-challenge With Immune-Checkpoints Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients: a Retrospective Observational Study https://ClinicalTrials.gov/show/NCT04069663 Completed University Hospital, Grenoble 2019-05-15
NCT04041297 Evaluation of NSCLC Patients’ Oxygen Uptake On-kinetics at Cycle-ergometer During Prehabilitation https://ClinicalTrials.gov/show/NCT04041297 Recruiting ADIR Association 2021-05-31
NCT04037150 Circulating DNA in Surgically Treated NSCLC https://ClinicalTrials.gov/show/NCT04037150 Recruiting Helsinki University Central Hospital 2020-12-31
NCT03989050 Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors https://ClinicalTrials.gov/show/NCT03989050 Recruiting University of Cologne 2020-08-31
NCT03987555 Paclitaxel Therapeutic Drug Monitoring in Cancer Patients https://ClinicalTrials.gov/show/NCT03987555 Recruiting Wake Forest University Health Sciences 2021-03-31
NCT03958565 Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations. https://ClinicalTrials.gov/show/NCT03958565 Recruiting University of Colorado, Denver 2022-03-05
NCT03951233 K-RAS and EGFR in Lung Cancer https://ClinicalTrials.gov/show/NCT03951233 Completed Hellenic Cooperative Oncology Group 2012-12-31
NCT03951012 Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy https://ClinicalTrials.gov/show/NCT03951012 Recruiting University of Iowa 2021-04-30
NCT03940846 CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology https://ClinicalTrials.gov/show/NCT03940846 Active, not recruiting Maastricht University 2020-10-31
NCT03918304 Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS https://ClinicalTrials.gov/show/NCT03918304 Recruiting AstraZeneca 2024-06-30
NCT03911219 Study to Evaluate the Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) Under 1st-line Treatment With Atezolizumab and Platinum-based Chemotherapy https://ClinicalTrials.gov/show/NCT03911219 Recruiting iOMEDICO AG 2024-06-30
NCT03892096 Development and Validation of a qPCR Cell Free DNA Assay as a Potential Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer https://ClinicalTrials.gov/show/NCT03892096 Active, not recruiting Cadex Genomics 2020-11-01
NCT03877250 Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies https://ClinicalTrials.gov/show/NCT03877250 Recruiting Memorial Sloan Kettering Cancer Center 2021-03-31
NCT03844464 Safety and Efficacy of Lorbrena https://ClinicalTrials.gov/show/NCT03844464 Recruiting Pfizer 2023-08-11
NCT03836469 Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil https://ClinicalTrials.gov/show/NCT03836469 Recruiting Latin American Cooperative Oncology Group 2020-06-03
NCT03833934 Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance https://ClinicalTrials.gov/show/NCT03833934 Recruiting Addario Lung Cancer Medical Institute 2020-08-23
NCT03804554 A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab https://ClinicalTrials.gov/show/NCT03804554 Active, not recruiting Bristol-Myers Squibb 2019-06-30
NCT03791034 Cell Free DNA for the Diagnosis and Treatment in Early NSCLC https://ClinicalTrials.gov/show/NCT03791034 Recruiting Samsung Medical Center 2020-12-31
NCT03790397 Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive https://ClinicalTrials.gov/show/NCT03790397 Completed Fundación GECP 2019-07-15
NCT03764917 NGS Combined With RNAseq on Tumor Immune Escape in NSCLC https://ClinicalTrials.gov/show/NCT03764917 Active, not recruiting Shanghai Pulmonary Hospital, Shanghai, China 2020-12-31
NCT03761901 Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium https://ClinicalTrials.gov/show/NCT03761901 Completed AstraZeneca 2019-06-19
NCT03746262 Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03746262 Completed Wake Forest University Health Sciences 2018-08-10
NCT03740503 Genomic Investigation of Unusual Responders https://ClinicalTrials.gov/show/NCT03740503 Active, not recruiting University Health Network, Toronto 2020-11-30
NCT03741647 Sleep Apnea and Lung Cancer https://ClinicalTrials.gov/show/NCT03741647 Active, not recruiting Zagazig University 2020-11-30
NCT03721289 Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients https://ClinicalTrials.gov/show/NCT03721289 Completed AstraZeneca 2019-03-09
NCT03710629 A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes https://ClinicalTrials.gov/show/NCT03710629 Recruiting The First Affiliated Hospital of Guangzhou Medical University 2022-12-01
NCT03705806 Palliative Thoracic ImmunoRT https://ClinicalTrials.gov/show/NCT03705806 Recruiting University Health Network, Toronto 2020-09-15
NCT03692442 Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform https://ClinicalTrials.gov/show/NCT03692442 Recruiting Guangzhou Institute of Respiratory Disease 2019-01-31
NCT03679936 Diagnostic Significance of Single Center, Open and Prospective Evaluation of 18F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03679936 Recruiting Fifth Affiliated Hospital, Sun Yat-Sen University 2020-12-31
NCT03689439 Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer? https://ClinicalTrials.gov/show/NCT03689439 Recruiting Fudan University 2021-11-01
NCT03658460 Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New Biomarkers https://ClinicalTrials.gov/show/NCT03658460 Recruiting Aalborg University Hospital 2019-10-01
NCT03647592 Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03647592 Recruiting Hunan Province Tumor Hospital 2021-08-31
NCT03647111 Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03647111 Recruiting Hunan Province Tumor Hospital 2020-12-31
NCT03647098 Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03647098 Enrolling by invitation Hunan Province Tumor Hospital 2020-12-31
NCT03645330 A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL) https://ClinicalTrials.gov/show/NCT03645330 Active, not recruiting Chugai Pharmaceutical 2021-06-15
NCT03646994 Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03646994 Recruiting Hunan Province Tumor Hospital 2020-12-31
NCT03616522 A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03616522 Completed Abramson Cancer Center of the University of Pennsylvania 2019-02-18
NCT03609918 Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing https://ClinicalTrials.gov/show/NCT03609918 Completed Tianjin Medical University Cancer Institute and Hospital 2017-09-27
NCT03576937 Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study https://ClinicalTrials.gov/show/NCT03576937 Recruiting University Health Network, Toronto 2020-07-31
NCT03562819 Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer). https://ClinicalTrials.gov/show/NCT03562819 Completed AstraZeneca 2019-06-07
NCT03512847 Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03512847 Recruiting Zealand University Hospital 2021-01-31
NCT03504098 Folate One-carbon Malnutrition as the Metabostemness Risk Factor of Malignancy Tumor Development of NSCLC Patients https://ClinicalTrials.gov/show/NCT03504098 Recruiting National Taiwan University Hospital 2020-07-31
NCT03499678 Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA https://ClinicalTrials.gov/show/NCT03499678 Recruiting HKGepitherapeutics 2020-12-01
NCT03492801 Collection of Blood Samples in Patients With Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03492801 Recruiting University of Southern California 2020-12-11
NCT03485326 A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients https://ClinicalTrials.gov/show/NCT03485326 Recruiting AstraZeneca 2021-06-30
NCT03465241 ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS https://ClinicalTrials.gov/show/NCT03465241 Recruiting Sun Yat-sen University 2021-12-31
NCT03457220 An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03457220 Completed AstraZeneca 2019-12-31
NCT03454685 The Role of Microbiota on the Development of Lung Cancer https://ClinicalTrials.gov/show/NCT03454685 Recruiting Wuhan Union Hospital, China 2020-01-30
NCT03451526 A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03451526 Completed Tang-Du Hospital 2017-12-01
NCT03427567 A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03427567 Completed Tongji Hospital 2017-12-01
NCT03429673 A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients https://ClinicalTrials.gov/show/NCT03429673 Completed China-Japan Friendship Hospital 2017-12-01
NCT03429192 A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03429192 Completed Tianjin Chest Hospital 2018-03-30
NCT03413956 An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03413956 Completed Jiangsu Cancer Institute & Hospital 2018-03-30
NCT01261585 Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT https://ClinicalTrials.gov/show/NCT01261585 Completed Centre Henri Becquerel 2009-11-30
NCT01260038 Study in NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in Region Antwerp, Belgium. https://ClinicalTrials.gov/show/NCT01260038 Completed University Hospital, Antwerp 2011-09-30
NCT01255150 Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01255150 Completed National Institutes of Health Clinical Center (CC) NA
NCT03872362 Radiomics Multifactorial Biomarker for Pulmonary Nodules https://ClinicalTrials.gov/show/NCT03872362 Completed Maastricht University 2019-01-11
NCT01194050 An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01194050 Completed Hoffmann-La Roche 2013-07-31
NCT01167972 Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma https://ClinicalTrials.gov/show/NCT01167972 Completed AstraZeneca 2012-09-30
NCT01153399 A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer). https://ClinicalTrials.gov/show/NCT01153399 Completed AstraZeneca 2014-12-31
NCT01146366 Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT01146366 Completed Washington University School of Medicine 2014-10-31
NCT01139944 Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01139944 Completed Alliance for Clinical Trials in Oncology 2014-01-31
NCT01139619 A Retrospective Study to Investigate the Current Situation of Biopsy Testing in Swedish Inoperable Non Small Cell Lung Cancer (NSCLC) Patients https://ClinicalTrials.gov/show/NCT01139619 Completed AstraZeneca 2013-01-31
NCT01124669 Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate https://ClinicalTrials.gov/show/NCT01124669 Completed Eastern Cooperative Oncology Group 2010-07-13
NCT01112631 Prospective Study of Quality of Life in Non-small Cell Lung Cancer (NSCLC) Patients Treated With/Without Postoperative Radiotherapy https://ClinicalTrials.gov/show/NCT01112631 Completed Maria Sklodowska-Curie Institute - Oncology Center 2007-09-30
NCT01103089 Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP) https://ClinicalTrials.gov/show/NCT01103089 Completed AstraZeneca 2010-12-31
NCT01081496 Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT01081496 Completed AstraZeneca 2010-08-31
NCT01069835 Epidemiological Study to Describe Non Small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Central Eastern Europe and Russia (Lung-EPICLIN) https://ClinicalTrials.gov/show/NCT01069835 Completed AstraZeneca 2011-03-31
NCT01067794 Chemotherapy in Treating Patients With Lung Cancer https://ClinicalTrials.gov/show/NCT01067794 Completed Eli Lilly and Company 2012-07-31
NCT01065415 Whole-Body Magnetic Resonance Imaging/Positron Emission Tomography (MRI/PET) in the Staging of Non-Small-Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT01065415 Completed Samsung Medical Center NA
NCT01026467 Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT01026467 Completed Wake Forest University Health Sciences 2014-05-31
NCT01023828 K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications https://ClinicalTrials.gov/show/NCT01023828 Completed National Institute of Cancerología 2010-01-31
NCT00997230 Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m https://ClinicalTrials.gov/show/NCT00997230 Completed AstraZeneca 2012-10-31
NCT00973427 DNA Chip Based Prognosis of Lung Cancer https://ClinicalTrials.gov/show/NCT00973427 Completed Medical Prognosis Institute A/S 2014-09-30
NCT00960271 Evaluation of Preoperative Endobronchial Ultrasound (EBUS) in Non Small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT00960271 Completed University Hospital, Rouen 2010-12-31
NCT00956280 Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00956280 Completed AstraZeneca 2010-04-30
NCT00923884 Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer https://ClinicalTrials.gov/show/NCT00923884 Completed National Institutes of Health Clinical Center (CC) NA
NCT00922025 Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients https://ClinicalTrials.gov/show/NCT00922025 Completed AstraZeneca 2010-12-31
NCT00897234 Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers https://ClinicalTrials.gov/show/NCT00897234 Completed University of Minnesota 2010-08-31
NCT00899756 Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00899756 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2016-12-31
NCT00890903 Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC) https://ClinicalTrials.gov/show/NCT00890903 Completed Pierre Fabre Pharma GmbH 2012-04-30
NCT00862030 CT-Based Versus Conventional Simulation for Palliative Radiotherapy of Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00862030 Completed AHS Cancer Control Alberta 2011-01-31
NCT03798535 First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy https://ClinicalTrials.gov/show/NCT03798535 Recruiting AstraZeneca 2023-12-20
NCT03724604 NSE/Alb as a Prognostic Biomarker for Lung Cancer https://ClinicalTrials.gov/show/NCT03724604 Recruiting First Affiliated Hospital Xi’an Jiaotong University 2019-06-30
NCT03724500 Clinical Significance of Circulating Tumor Cell in Non Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03724500 Recruiting Chang Gung Memorial Hospital 2020-12-31
NCT01106781 A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology https://ClinicalTrials.gov/show/NCT01106781 Completed AstraZeneca 2014-01-31
NCT00831909 Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN https://ClinicalTrials.gov/show/NCT00831909 Completed AstraZeneca 2010-07-31
NCT00831454 Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection https://ClinicalTrials.gov/show/NCT00831454 Completed Istituto Clinico Humanitas 2011-12-31
NCT04294108 Why in Hospital After VATS Lobectomy https://ClinicalTrials.gov/show/NCT04294108 Recruiting Rigshospitalet, Denmark 2020-09-16
NCT02751879 Real World Data on Gi(l)Otrif® Dose Adjustment https://ClinicalTrials.gov/show/NCT02751879 Completed Boehringer Ingelheim 2017-09-30
NCT01522833 Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer https://ClinicalTrials.gov/show/NCT01522833 Completed SCRI Development Innovations, LLC 2015-02-28
NCT01505400 Integrated Molecular Profiling in Advanced Cancers Trial https://ClinicalTrials.gov/show/NCT01505400 Active, not recruiting University Health Network, Toronto 2021-01-31
NCT03916367 CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer https://ClinicalTrials.gov/show/NCT03916367 Completed Peking University Third Hospital 2018-12-15
NCT03870464 LIFE - Lung Cancer, Immunotherapy, Frailty, Effect https://ClinicalTrials.gov/show/NCT03870464 Recruiting University of Southern Denmark 2021-09-30
NCT03838588 The Tracking Molecular Evolution for NSCLC (T-MENC) Study https://ClinicalTrials.gov/show/NCT03838588 Recruiting Geneplus-Beijing Co. Ltd. 2021-12-31
NCT03727477 Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib https://ClinicalTrials.gov/show/NCT03727477 Recruiting Intergroupe Francophone de Cancerologie Thoracique 2020-06-30
NCT02689050 Optical Biopsy for Thoracic Lymph Nodes. https://ClinicalTrials.gov/show/NCT02689050 Completed Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 2017-03-22
NCT02440854 Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings https://ClinicalTrials.gov/show/NCT02440854 Active, not recruiting Boehringer Ingelheim 2021-03-22
NCT04266691 Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT04266691 Completed Zhejiang Cancer Hospital 2015-12-31
NCT04023812 Stage III NSCLC RWE in Chinese Patients https://ClinicalTrials.gov/show/NCT04023812 Recruiting AstraZeneca 2022-05-30
NCT03939481 Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer https://ClinicalTrials.gov/show/NCT03939481 Recruiting Southwest Oncology Group 2025-02-28
NCT03725475 A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients https://ClinicalTrials.gov/show/NCT03725475 Completed AstraZeneca 2019-09-30
NCT03613467 Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients https://ClinicalTrials.gov/show/NCT03613467 Completed Tang-Du Hospital 2018-07-04
NCT03559647 The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy https://ClinicalTrials.gov/show/NCT03559647 Active, not recruiting Hoffmann-La Roche 2023-05-12
NCT00763607 Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT00763607 Completed Istituto Clinico Humanitas 2008-02-29
NCT00759382 Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study. https://ClinicalTrials.gov/show/NCT00759382 Active, not recruiting European Lung Cancer Working Party 2021-01-31
NCT00717847 A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib https://ClinicalTrials.gov/show/NCT00717847 Completed National University Hospital, Singapore 2013-04-30
NCT00717002 Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study https://ClinicalTrials.gov/show/NCT00717002 Completed National University Hospital, Singapore 2013-04-30
NCT00671242 Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake https://ClinicalTrials.gov/show/NCT00671242 Completed Gunma University NA
NCT00641238 Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA) https://ClinicalTrials.gov/show/NCT00641238 Completed State University of New York - Upstate Medical University 2011-02-28
NCT00602433 Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib https://ClinicalTrials.gov/show/NCT00602433 Completed Northwestern University 2009-08-31
NCT00603057 Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer https://ClinicalTrials.gov/show/NCT00603057 Completed University of Michigan Rogel Cancer Center 2013-09-30
NCT00579683 Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00579683 Completed Memorial Sloan Kettering Cancer Center 2016-02-29
NCT00572325 Concurrent Chemo-radiation Form NSCLC to a Individualized MLD https://ClinicalTrials.gov/show/NCT00572325 Completed Maastricht Radiation Oncology NA
NCT00573040 Radiotherapy for NSCLC to a Individualized MLD https://ClinicalTrials.gov/show/NCT00573040 Completed Maastricht Radiation Oncology NA
NCT00501319 Measurement of Pain and Other Symptoms of Non-Small Cell Lung Cancer (NSCLC) Patients Following Thoracic Surgery https://ClinicalTrials.gov/show/NCT00501319 Completed M.D. Anderson Cancer Center 2011-10-31
NCT00464282 Fluorine-18-α–Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer https://ClinicalTrials.gov/show/NCT00464282 Completed Gunma University NA
NCT00450281 S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00450281 Completed Southwest Oncology Group 2012-07-31
NCT00419042 Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT00419042 Completed Groupe Francais De Pneumo-Cancerologie 2006-09-30
NCT00418704 Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT00418704 Completed Groupe Francais De Pneumo-Cancerologie 2006-06-30
NCT00409968 BATTLE Program: Umbrella Protocol for Patients With Non-Small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT00409968 Completed M.D. Anderson Cancer Center 2019-10-31
NCT00388206 A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) https://ClinicalTrials.gov/show/NCT00388206 Completed Genentech, Inc. 2012-03-31
NCT00351598 Lung Tumour Volume Database https://ClinicalTrials.gov/show/NCT00351598 Completed Trans-Tasman Radiation Oncology Group (TROG) 2009-02-28
NCT00352391 Vanguard Study for Head and Neck Cancer or Non-Small Cell Lung Cancer (NSCLC) Patients https://ClinicalTrials.gov/show/NCT00352391 Completed M.D. Anderson Cancer Center 2016-01-31
NCT00341380 Prevention of Tumor Spread Due to Lung Cancer Surgery https://ClinicalTrials.gov/show/NCT00341380 Completed National Institutes of Health Clinical Center (CC) 2007-04-13
NCT00280202 Detection of Genetic Markers of Lung Cancer https://ClinicalTrials.gov/show/NCT00280202 Recruiting University of Pittsburgh 2050-12-31
NCT00263731 Metabolomic Analysis of Lung Cancer https://ClinicalTrials.gov/show/NCT00263731 Recruiting University of Louisville 2025-12-31
NCT00252759 Iressa Case Control Study in Japan https://ClinicalTrials.gov/show/NCT00252759 Completed AstraZeneca NA
NCT00222404 Pharmacogenomic Study Realized on “Non-small Cell Lung Carcinoma” https://ClinicalTrials.gov/show/NCT00222404 Completed University Hospital, Grenoble NA
NCT00213733 Molecular Assessment of Lymph Nodes in Patients With Resected (Stage I to IIIA) Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT00213733 Completed University Hospital, Strasbourg, France NA
NCT00094822 Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT00094822 Completed Amgen 2005-12-31
NCT00077324 Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions https://ClinicalTrials.gov/show/NCT00077324 Completed Alliance for Clinical Trials in Oncology 2011-11-30
NCT01936571 Usefulness of Blood Biomarkers for Overall Survival in NSCLC https://ClinicalTrials.gov/show/NCT01936571 Completed Maastricht Radiation Oncology 2014-02-28
NCT00071344 Analysis of Brain Metastasis in Patients With Lung Cancer https://ClinicalTrials.gov/show/NCT00071344 Completed National Institutes of Health Clinical Center (CC) NA
NCT00818402 Non-small Cell Lung Cancer and Quality of Life https://ClinicalTrials.gov/show/NCT00818402 Completed University of Turku 2012-02-29

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03824977 Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery https://ClinicalTrials.gov/show/NCT03824977 Recruiting University Hospital, Rouen 2018-11-21
NCT03334864 Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG) https://ClinicalTrials.gov/show/NCT03334864 Recruiting Peking Union Medical College Hospital 2023-12-31
NCT03299478 Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03299478 Recruiting University Hospital of North Norway 2024-11-30
NCT03235765 Cancer Panel From Blood of Lung Cancer Patients https://ClinicalTrials.gov/show/NCT03235765 Active, not recruiting Seoul National University Hospital 2019-03-10
NCT03125603 Side Effects of Anti-PD-(L)-1 and Anti CTLA-A4 in the Non Small Cells Lung Cancer https://ClinicalTrials.gov/show/NCT03125603 Completed Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2018-08-01
NCT03066297 Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03066297 Recruiting Samsung Medical Center 2027-02-15
NCT02991924 Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer https://ClinicalTrials.gov/show/NCT02991924 Active, not recruiting National Cancer Center, Korea 2019-12-31
NCT02965391 Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients https://ClinicalTrials.gov/show/NCT02965391 Completed Peking University People’s Hospital 2017-09-30
NCT02778854 Liquid Biopsy for Detection of Driver Mutation in NSCLC https://ClinicalTrials.gov/show/NCT02778854 Recruiting Chinese PLA General Hospital 2018-12-31
NCT02777658 PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC https://ClinicalTrials.gov/show/NCT02777658 Completed AstraZeneca 2020-05-31
NCT02730897 Multicentric Analysis of Predictors of N1 Upstaging After Resection of cStage-I NSCLC https://ClinicalTrials.gov/show/NCT02730897 Completed University Hospital, Gasthuisberg 2016-10-31
NCT02622581 Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients https://ClinicalTrials.gov/show/NCT02622581 Recruiting AIO-Studien-gGmbH 2023-09-30
NCT02113852 Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients https://ClinicalTrials.gov/show/NCT02113852 Completed Guangdong Association of Clinical Trials 2016-05-31
NCT01963351 Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLC https://ClinicalTrials.gov/show/NCT01963351 Completed University of Athens 2014-01-31
NCT01951755 Phase IV Study of Tarceva in Patients With Advanced Stage IIIB/ IV Non-small Cell Lung Cancer (NSCLC) https://ClinicalTrials.gov/show/NCT01951755 Completed University of Athens 2014-01-31
NCT01838577 Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study https://ClinicalTrials.gov/show/NCT01838577 Active, not recruiting European Organisation for Research and Treatment of Cancer - EORTC 2018-10-31
NCT01808677 Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy https://ClinicalTrials.gov/show/NCT01808677 Completed M.D. Anderson Cancer Center 2016-08-31
NCT04266483 Cancer Genome Atlas of China:Lung Cancer https://ClinicalTrials.gov/show/NCT04266483 Recruiting Xuanwu Hospital, Beijing 2022-11-08
NCT04216121 LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib https://ClinicalTrials.gov/show/NCT04216121 Recruiting Universitaire Ziekenhuizen Leuven 2023-02-28
NCT04153097 Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC https://ClinicalTrials.gov/show/NCT04153097 Recruiting First Affiliated Hospital of Zhejiang University 2020-11-30
NCT04137588 Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT04137588 Recruiting Beijing Cancer Hospital 2022-03-01
NCT03995875 Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC https://ClinicalTrials.gov/show/NCT03995875 Recruiting AstraZeneca 2023-12-31
NCT03791151 Pharmacogenetics in Non Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT03791151 Recruiting Ain Shams University 2019-11-30
NCT03643484 IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy https://ClinicalTrials.gov/show/NCT03643484 Active, not recruiting AstraZeneca 2021-06-30
NCT03605602 A Real World Study Based on NGS (TRUMPRWS) https://ClinicalTrials.gov/show/NCT03605602 Recruiting Guangdong Association of Clinical Trials 2022-12-30
NCT03305380 Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth https://ClinicalTrials.gov/show/NCT03305380 Recruiting Maastricht Radiation Oncology 2020-12-01